Matrix bound vesicles (MBVS) containing il-33 and use thereof

Membrane-bound nanovesicles from ECM, enriched with IL-33, address the challenge of fibrosis and graft rejection by activating M2-like macrophages, promoting tissue repair and reducing inflammation, offering a therapeutic solution for cardiac injuries and transplant rejection.

JP2024159910APending Publication Date: 2024-11-08UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024140826
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-05-03
Filing Date
2024-08-22
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Current therapies are inadequate for preventing or reversing fibrosis caused by cardiac injury, such as myocardial infarction or immune-mediated rejection after heart transplantation, and there is a need for effective immunomodulatory agents that can promote tissue repair without immunosuppression.

Method used

The use of membrane-bound nanovesicles (MBVs) derived from extracellular matrix (ECM) containing interleukin-33 (IL-33) to activate a pro-remodeling macrophage phenotype through a non-canonical ST2-independent pathway, promoting tissue repair and inhibiting fibrosis.

Benefits of technology

MBVs containing IL-33 effectively reduce fibrosis and inflammatory responses, enhancing tissue remodeling and graft survival by activating M2-like macrophages, thereby preventing and treating fibrotic diseases and graft rejection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024159910000001
    Figure 2024159910000001
  • Figure 2024159910000002
    Figure 2024159910000002
  • Figure 2024159910000003
    Figure 2024159910000003
Patent Text Reader

Abstract

To provide methods for treating a subject with a disorder, such as a) fibrosis in organ or tissue; b) solid organ transplant rejection; or c) a cardiac disease that is not myocardial infarction or myocardial ischemia.SOLUTION: These methods include the step for selecting a subject having or at risk of having the disorder, and the step for administering to the subject a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix, wherein the nanovesicles contain interleukin (IL)-33 and comprise lysyl oxidase, and wherein the nanovesicles a) do not express CD63 or CD81, or b) are CD63loCD81lo. In additional embodiments, methods are disclosed for increasing myoblast differentiation.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62 / 666,624, filed May 3, 3018, which is incorporated herein by reference in its entirety. Government support statement

[0002] This invention was made with Government support under grant nos. AR073527 and HL122489 awarded by the National Institutes of Health. The Government has certain rights in this invention.

[0003] The present invention relates to the use of membrane-bound nanovesicles (MBVs) containing interleukin (IL)-33 for treating a) organ or tissue fibrosis, b) solid organ transplant rejection, and c) cardiac disease. [Background technology]

[0004] Cardiac disease or injury causes fibrosis, resulting in myocardial stiffness, loss of function, and heart failure (HF). Replacement fibrosis occurs after myocardial ischemia (MI) when damaged cardiac myocytes are replaced by fibroblasts and associated excess extracellular matrix (ECM) (Travers et al., Circulation research 118, 1021-1040 (2016)). Reactive interstitial fibrosis affects the surrounding areas of the microvasculature and the local myocardium, contributing to chronic allograft rejection (CR) after heart transplantation (HTx). CR causes over 50% graft loss within 11 years of transplantation (Libby and Pober, Immunity 14, 387-397 (2001)). Excessive inflammation has been implicated in adverse cardiac remodeling and progression to HF. Numerous experimental studies have shown that timely resolution of inflammation after MI or HTx can help prevent the development and progression of immune-driven fibrosis (Frangogiannis, Nature Reviews Cardiology 11, 255 (2014); Suthahar, Current Heart Failure Reports 14, 235-250 (2017)). However, there are no effective therapeutic modalities available to prevent or reverse fibrosis resulting from cardiac injury after MI or ischemia-reperfusion injury (IRI) and immune-mediated attack after HTx.

[0005] Biological scaffolds composed of mammalian extracellular matrix (ECM) have been developed as surgical mesh materials, powders for localized wound care, and hydrogels, all of which have applications in aortic and mitral valve replacement (Gerdisch et al., J. of thoracic and cardiovascular surgery 148, 1370-1378 (2014);Brown et al., The Annals of thoracic surgery 91, 416-423 (2011)), reconstruction of congenital heart defects (Scholl et al., World Journal for Pediatric and Congenital Heart Surgery 1, 132-136 (2010)), and as cardiac patches to reinforce the native pulmonary valve during primary repair of tetralogy of Fallot (TOF) (Dharmapuram et al., World Journal for Pediatric and Congenital Heart Surgery 8, 174-181 (2013)). (2017)). ECM hydrogels have been shown to directly promote endogenous repair of the myocardium (Ungerleider & Christman;Stem Cells Transl Med 3, 1090-1099 (2014);Hernandez & Christman, JACC Basic Transl Sci 2, 212-226 (2017);Wassenaar et al., J Am Coll Cardiol 67, 1074-1086 (2016)) and are currently being investigated in a Phase I clinical trial for intracardiac injection to facilitate cardiac tissue repair after myocardial infarction (ClinicalTrials.gov Identifier: NCT02305602). These ECM-based materials are most commonly of xenogeneic origin and are prepared by decellularization of source tissues such as the dermis, bladder or small intestinal submucosa (SIS), among others (Keane et al., Methods 84, 25-34 (2015)).Xenogeneic ECM scaffolds do not elicit deleterious innate or adaptive immune responses and, in fact, support anti-inflammatory and reparative innate and adaptive immune responses (Huleihel et al., in Seminars in Immunology, 39:2-13 (2017)). The use of these naturally occurring biomaterials is generally accompanied by at least partial reconstruction of functional, site-appropriate tissue, a process termed "structural remodeling" (Martinez et al., F1000 Prime Rep 6 :13 (2014)). Arguably, the primary determinant of downstream functional remodeling outcomes is the early innate immune response to the ECM bioscaffold (Brown, et al., Acta Biomater, 8:978-987(2012)). ECM bioscaffolds, or their degradation products, have been shown to direct tissue repair by promoting the conversion of pro-inflammatory M1-like macrophages and Th1 T cell phenotypes to pro-remodeling M2-like macrophages and T helper type 2 (Th2) cell responses (Huleihel, et al. Seminars in Immunology, 29:2-13(2017)). Numerous studies have demonstrated that timely conversion of macrophages to an activated state is necessary to promote tissue remodeling and wound healing processes rather than scar tissue formation in multiple anatomical sites, including skeletal muscle (Kuswanto et al., Immunity 44, 355-367 (2016); Serrels et al., Sci. Signal. 10, 508 (2017)), and the cardiovascular system (Oboki et al., Proceedings of the National Academy of Sciences 107, 18581-18586 (2010); Townsend et al., Journal of Experimental Medicine 191, 1069-1076 (2000)).This conversion is not immunosuppressive but rather a constitutive form of immune regulation that promotes a phenotypic change in the local macrophage phenotype (Oliveira et al., PloS one 8, e66538 (2013);Reing et al., Biomaterials 31, 8626-8633 (2010)). However, it was previously unknown which components of the ECM have this function. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Travers et al., Circulation research 118, 1021-1040 (2016) [Non-Patent Document 2] Libby and Pober, Immunity 14, 387-397 (2001) [Non-Patent Document 3] Frangogiannis, Nature Reviews Cardiology 11, 255 (2014) Summary of the Invention [Means for solving the problem]

[0007] Methods are disclosed for treating or inhibiting a disorder in a subject having or at risk of having the disorder. In some embodiments, the disorder is a) organ or tissue fibrosis; b) solid organ graft rejection; or c) cardiac disease that is not myocardial infarction or myocardial ischemia. These methods include selecting a subject having or at risk of having the disorder and administering to the subject a therapeutically effective amount of isolated nanovesicles derived from extracellular matrix, wherein the nanovesicles comprise interleukin (IL)-33, and the nanovesicles a) do not express CD63 or CD81, or b) express CD63 or CD81. lo CD81 lo It is.

[0008] In additional embodiments, methods for increasing myoblast differentiation are disclosed, comprising contacting myoblasts with an effective amount of isolated extracellular matrix derived nanovesicles, wherein the nanovesicles comprise interleukin (IL)-33 and comprise lysyl oxidase, and the nanovesicles a) do not express CD63 or CD81, or b) express CD63 lo CD81 lo It is.

[0009] In some non-limiting examples, the nanovesicles maintain expression of CD68 and CD11b on macrophages in the subject.

[0010] The foregoing and other features and advantages will become more apparent from the following detailed description of several embodiments, which proceeds with reference to the accompanying drawings. [Brief description of the drawings]

[0011] [Figure 1-1]Figures 1A-1E show that MBVs isolated from ECM bioscaffolds contain full-length IL-33. A, Cytokine array. Cytokine cargo of MBVs isolated from decellularized WT mouse intestine (n=3) or decellularized IL-33- / - mouse intestine (n=3) was analyzed using Mouse XL Cytokine Array Kit from R&D system. The array contains 111 cytokines spotted in duplicate. Boxed area indicates location of IL-33 spots. B, Graphical representation of quantification of 15 cytokines with highest expression levels in MBVs isolated from decellularized WT or IL33- / - mouse intestine. C, Transmission electron microscopy imaging of MBVs isolated from decellularized WT mouse intestine. Arrows indicate MBVs. D, Immunoblot analysis of IL-33 expression levels in MBVs isolated from three decellularized WT mouse intestines or three IL33- / - mouse intestines. E, Immunoblot analysis of IL-33 expression levels in MBVs isolated from laboratory-generated porcine urinary bladder matrix (UBM), small intestinal submucosa (SIS), dermis, and myocardial ECM and three commercially available biological scaffold equivalents: ACELL® MATRISTEM™ (porcine bladder), BD® XENMATRIX™ (porcine dermis), and COOK BIOTECH® BIODESIGN™. [Figure 1-2] Same as above. [Figure 1-3] Same as above.

[0012] [Figure 2-1]2A-2E show that full-length IL-33 stored in the ECM is protected from proteolysis by incorporation into the lumen of MBV. A, MBV were fractionated by molecular sieve chromatography (SEC) and elution fractions were continuously monitored by UV absorbance at 280 nm. Thirty 500 μl fractions were collected. In a separate experiment, MBV was first dissolved using TRITON® X-100 and then fractionated by SEC. An overlay of the two UV chromatograms shows that intact MBV eluted in the heavier fraction, while the molecular components of dissolved MBV eluted mainly in the lighter fraction. B, Elution fractions from chromatographed intact MBV (upper panel) or dissolved MBV (lower panel) were pooled as indicated and analyzed by immunoblot for IL-33. C, Pooled fractions 6-8 of chromatographed intact MBV were imaged by transmission electron microscopy. D) Pooled fractions 6-8 of intact MBVs were either directly biotinylated to label MBV surface proteins or first lysed with TRITON® X-100 and MBV extracts were biotinylated to label luminal and surface proteins. Proteins isolated after streptavidin pull-down (SA) and the unbound fraction (unbound), representing proteins that did not bind to streptavidin beads, were analyzed by immunoblot for the presence of IL-33. Arrows indicate MBV. E, Proteinase K protection assay. Pooled fractions 6-8 of chromatographed intact MBVs were treated with the indicated concentrations of proteinase K in the absence or presence of TRITON® X-100. Samples were analyzed by immunoblot for IL-33. [Figure 2-2] Same as above. [Figure 2-3] Same as above.

[0013] [Figure 3-1]Figures 3A-3D show that MBVs containing luminal IL-33 activate a pro-remodeling macrophage phenotype (F4 / 80+iNOS-Arg+) by a non-canonical ST2-independent pathway. a, b, Bone marrow-derived macrophages (BMDMs) harvested from WT mice (A) or ST2- / - mice (B) were left untreated (control) or treated for 24 h with the following test articles: IFNγ+LPS, IL-4, IL-33, MBVs isolated from decellularized WT mouse intestine (WT MBVs), MBVs isolated from decellularized IL-33- / - mouse intestine (IL-33- / - MBVs), or MBVs isolated from porcine small intestinal submucosa (SIS MBVs). Cells were immunolabeled with F4 / 80 (macrophage marker), iNos (M1 marker), or Arg1 (M2 marker). C, Quantification of iNOS immunolabeling shows a significant increase in iNOS expression in both WT and ST2- / - BMDMs after treatment with IFNγ+LPS or MBVs isolated from IL-33- / - mice compared to the negative control (treatment with IL-4) (compared to negative control, ** indicates p<0.01, * indicates p<0.05, error bars represent SEM, n=3). D, Quantification of arginase immunolabeling shows a significant increase in arginase expression in both WT and ST2- / - BMDMs after treatment with IL-4 or MBVs isolated from WT mice compared to the negative control (IFNγ+LPS) (compared to negative control, ** indicates p<0.01, error bars represent SEM, n=3). [Figure 3-2] Same as above. [Figure 3-3] Same as above.

[0014] [Figure 4]Figures 4A-4B show that MBVs containing IL-33 upregulate Arg1 expression in a Stat6 phosphorylation-independent manner. A, B, Bone marrow-derived macrophages (BMDMs) harvested from WT or ST2- / - mice were left untreated (control) or stimulated for 24 h (A) or 30 min (B) with IL4, IL-33, MBVs isolated from decellularized WT mouse intestine (WT MBV), or MBVs isolated from decellularized IL-33- / - mouse intestine (IL-33- / - MBV). Cell lysates were analyzed by immunoblot for arginase-1 and ST2 expression (A) and phosphorylation of Stat6 (B).

[0015] [Figure 5-1] Figures 5A-5B show that secretions from WT MBV-treated macrophages are myogenic with respect to progenitor cells. A, B, C2C12 myoblasts were cultured to confluence and treated with proliferation medium, differentiation medium, or medium conditioned by polarized, MBV-treated macrophages. Cells were differentiated and immunolabeled for sarcomeric myosin. [Figure 5-2] Same as above.

[0016] [Figure 6-1]Figure 6A-6D: Total absence of graft IL-33 leads to increased fibrosis and vasculopathy associated with chronic rejection. A-D, IL-33+Bm12 (il33+ / +Bm12) or IL-33-deficient Bm12 (il33- / -Bm12) grafts were transplanted into C57BL / 6 (B6) IL-33-expressing recipients (WT B6) or C57BL / 6 (B6) IL-33-deficient recipients (il33- / -B6) (n=6 / group). Grafts were harvested on post-operative day (POD) 90-100 and evaluated after H&E (A,B), Masson's trichrome (A,B). Naive il33- / -Bm12 hearts were stained as controls. (C) Vascular occlusion and (D) fibrotic area percentages were quantified by NEARCYTE software. "*" indicates significant differences between the il33+ / +Bm12 group and the WT B6 group, and P values ​​were generated by one-way analysis of variance (ANOVA), *P<0.01, **P<0.005. [Figure 6-2] Same as above.

[0017] [Figure 7]Figure 7A-7D. Total absence of graft IL-33 led to an increase in local inflammatory myeloid cells early after heart transplantation. A-D, Wild-type (WT) IL-33+ Bm12 grafts and IL-33-deficient knockout (KO) Bm12 grafts were transplanted into WT B6 recipients (n=4-5 / group). On postoperative day (POD) 3, graft-infiltrating leukocytes were assessed by flow cytometry analysis. Leukocytes isolated from the hearts of naive Bm12 mice were included as baseline controls (control; n=4). A. Representative dot plots from each group show the frequency of CD11b+CD11c+ cells found in the CD45+ parent gating. B. Representative dot plots from cells gated on CD11b+CD11c+ show that the increased CD11c+ cells are primarily MHCIIhi monocyte-derived dendritic cells (monoDCs) and CD11chi inflammatory macrophages. Arrows indicate the parent population from which the gated cells were derived. C-D. Representative dot plots from cells gated on CD11b+CD11clo show that in the absence of IL-33, the frequency of pro-inflammatory F4-80+ macrophages, including the Ly6chiMHCIIhi subset, was increased in cardiac grafts. P values ​​were generated by one-way analysis of variance (ANOVA), *P<0.05.

[0018] [Figure 8-1]Figures 8A-8D show that administration of IL33+MBV limits the generation of pro-inflammatory infiltrating myeloid cells early after transplantation. A-D, Wild-type (WT) IL-33+Bm12 grafts, IL-33-deficient knockout (KO) Bm12 grafts alone, or IL-33-deficient KO Bm12 grafts treated with WT IL-33+MBV in hydrogel (IL33(hydrogel)) were transplanted into WT B6 recipients (WT; n=4-6 / group). On postoperative day (POD) 3, graft-infiltrating leukocytes and splenocytes were assessed by flow cytometric analysis. Leukocytes from the heart and spleen of naive Bm12 mice were also included as baseline controls (control; n=3-9). Representative dot plots show the frequency (%) of monocyte-derived dendritic cells (DCs) (A) in CD45.2+Lineage-Ly6G-gating and macrophage subsets (B) in CD45.2+Lineage-Ly6G-CD11c-CD11b+gating as well as graft-infiltrating and recipient splenocytes (C-D). The figure shows a summary of statistics for the changes in DCs (C) in macrophage subsets (D). P values ​​for the data shown were generated by one-way analysis of variance (ANOVA) and were *P<0.05, **P<0.01, ***P<0.005, ****P<0.001. [Figure 8-2] Same as above. [Figure 8-3] Same as above. [Figure 8-4] Same as above.

[0019] [Figure 9-1]9A-9B are graphs showing fibrosis treatment. Human lung fibroblasts from lungs explanted from IPF patients and age-matched controls (n=2). (A) Expression levels of Col1, Col3, and ACTA2 were determined before treatment. (B) Fibroblasts were treated with matrix-bound nanovesicles (MBVs) of different origin: porcine decellularized bladder matrix (pUBM ECM), porcine decellularized lung (pLung) and human lung tissue (hLung) at different doses: 1x109 and 3x109 particles per ml. After 48 hours of treatment, cells were harvested and RNA was isolated to analyze by qRT-PCR for expression of senescence and fibrosis marker transcripts. *p<0.5, **p<0.01, ***p<0.001. [Figure 9-2] Same as above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] Sequence Listing The nucleic acid and amino acid sequences listed in the attached sequence listing are shown using standard letter abbreviations for nucleotide bases and three-letter code for amino acids as defined in 37 C.FR1.822. Only one strand of each nucleic acid sequence is shown, but it is understood that any reference to the shown strand includes the complementary strand. The sequence listing is submitted as an ASCII text file [7123-100723-02sequencelisting.txt, May 2, 2019, 4.0 kb] and is incorporated herein by reference. In the attached sequence listing: SEQ ID NOs: 1 to 3 are miRNA sequences.

[0021] Degradation of ECM scaffolding materials and the subsequent release of nanovesicles with bioactive components, also referred to as "matrix-bound nanovesicles" or "MBVs", results in the activation of a reparative and anti-inflammatory M2 macrophage phenotype. MBVs are nanometer-sized membranous vesicles that are embedded in the collagen network of the ECM and protect biologically active signaling molecules (microRNAs and proteins) from degradation and denaturation. ECM bioscaffolds and the MBVs present within them can activate macrophages to an M2-like pro-remodeling phenotype. It is disclosed herein that these MBVs can be used to target infiltrating recipient bone marrow cell populations and / or inhibit allograft fibrotic disease after solid organ transplantation. The disclosed methods can prevent and / or treat allograft fibrotic disease after solid organ transplantation.

[0022] It is disclosed herein that MBVs are a rich source of extranuclear interleukin-33 (IL-33). IL-33 is an IL-1 family member that is typically found in the nuclei of stromal cells and is generally considered an alarmin or autologous molecule that is released after tissue injury to activate immune cells via the IL-33 receptor, ST2 (Wainwright et al., Tissue Engineering Part C: Methods 16, 525-532 (2009)). IL-33 binds to ST2, a cellular signaling pathway that activates immune cells. +It promotes graft survival after cardiac transplantation by stimulating regulatory T cells (Tregs) (Wainwright et al., Tissue Engineering Part C: Methods 16, 525-532 (2009); Boeing et al., Journal of Extracellular Vesicles 3, 23430 (2014). Intracellular IL-33 protein has been suggested to modulate gene expression through interaction with chromatin or signaling molecules via the N-terminus of IL-33 (Jong et al., Journal of Cellular and Molecular Medicine 20, 342-350 (2016)). It is disclosed herein that IL-33, stably stored in the ECM and protected from proteolytic cleavage by incorporation into MBVs, is a potent mediator of M2 macrophage activation through an uncharacterized non-canonical ST2-independent pathway.

[0023] il33 + / + MBV isolated from mouse tissue ECM are st2 - / - Directs macrophage activation toward a pro-reparative remodeling M2 activation state, whereas il33 - / - MBV isolated from mouse tissue ECM are st2 - / - IL33 does not direct macrophage activation towards the pro-reparative remodeling M2 activation state + MBV generates M2-like macrophages in a Stat6 phosphorylation-independent manner, and this IL33 + The capacity of MBV is distinct from the well-characterized IL-4 / IL-13-mediated M2 macrophage differentiation pathway. Furthermore, in a mouse heart transplantation model, IL-33-deficient grafts showed a significant increase in early graft infiltration by proinflammatory myeloid cells, including M1-like macrophages and monocyte-derived DCs. IL-33 expression was significantly increased after transplantation of IL-33-deficient heart grafts. +MBV administration significantly reduced the frequency of proinflammatory myeloid cells in the graft, thus demonstrating the potential of IL33 after solid organ transplantation, including, but not limited to, heart transplantation. + MBV delivery can inhibit and / or prevent bone marrow activation during rejection, such as acute or chronic graft rejection.

[0024] Furthermore, MBV can be used to control local inflammation and support soft tissue repair after surgical procedures involving injury or allogeneic solid organ transplantation. The use of MBV allows induction of ST2-independent gene expression in myeloid cells by IL-33. As a result, this treatment shifts the myeloid compartment away from typical pro-inflammatory deleterious subsets (i.e., M1 macrophages, inflammatory monocytes, and inflammatory monocyte-derived dendritic cells) at the site of trauma or ischemic injury, and toward beneficial reparative or regulatory subsets (i.e., M2 macrophages and Ly6c lo This technique can limit subsequent fibrotic disease by shifting the number of cells in the blood to monocytes. This technique also supports soft tissue and muscle repair at the defect site by similar modification of local bone marrow cells.

[0025] Matrix-bound nanovesicles (MBVs) are embedded in the fibrous network of ECM. These nanoparticles shield their cargo from degradation and denaturation during the ECM scaffold manufacturing process. Exosomes are microvesicles previously identified almost exclusively in body fluids and cell culture supernatants. MBVs and exosomes have been demonstrated to be distinct. MBVs differ from other microvesicles because, for example, they are resistant to detergent and / or enzyme digestion, contain distinct clusters of microRNAs, and are enriched in miR-145. MBVs do not have the characteristic surface proteins found on other microvesicles, such as exosomes. As disclosed herein, MBVs affect cell survival and modulate healing responses to preserve or restore neurological function. It is disclosed that MBVs differentially regulate RGC survival, axonal growth, and tissue remodeling. term

[0026] The following explanation of terms and methods is provided to better describe the present disclosure and to guide those skilled in the art in practicing the disclosure. The singular forms "a", "an" and "the" refer to one or more than one, unless the context clearly dictates otherwise. For example, the term "comprising a cell" includes a single cell or multiple cells and is considered equivalent to the phrase "comprising at least one cell". The term "or" refers to a single element or a combination of two or more elements of the indicated element options, unless the context clearly dictates otherwise. As used herein, "comprises" means "includes". Thus, "comprising A or B" means "including A, B, or A and B" without excluding additional elements. The dates of GENBANK® accession numbers referred to herein are sequences available at least as early as September 16, 2015. All references, patent applications and publications cited herein, and GENBANK® accession numbers are incorporated by reference. In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided.

[0027] Animal: A living multi-cellular vertebrate organism, a category that includes, for example, mammals and birds. The term mammal includes both human and non-human mammals. Similarly, the term "subject" includes both human and animal subjects.

[0028] Biocompatible: Any material that, when implanted in a mammalian subject, does not elicit an adverse response in the subject. A biocompatible material is capable of performing its intended function when introduced into an individual and is not toxic or injurious to that individual, nor does it induce immunological rejection of the material in the subject.

[0029] Cardiac disease or disorder: disease or disorder that negatively affects the cardiovascular system. This term is also intended to refer to cardiovascular events such as acute coronary syndrome, myocardial infarction, myocardial ischemia, chronic stable angina, unstable angina, angioplasty, stroke, transient ischemic attack, claudication and vascular occlusion. Thus, cardiac disease and disorder can include acute coronary syndrome, myocardial infarction, myocardial ischemia, chronic stable angina, unstable angina, angioplasty, transient ischemic attack, ischemic reperfusion injury, claudication, vascular occlusion, arteriosclerosis, heart failure, chronic heart failure, acute decompensated heart failure, cardiac hypertrophy, cardiac fibrosis, aortic valve disease, aortic or mitral valve stenosis, cardiomyopathy, atrial fibrillation, heart arrhythmia, and pericardial disease.

[0030] Cardiac dysfunction: any dysfunction of the pumping function of the heart. Cardiac dysfunction includes, for example, contractile dysfunction, relaxation dysfunction (sometimes called diastolic dysfunction), abnormal or improper function of the heart's valves, diseases of the heart muscle (sometimes called cardiomyopathies), diseases such as angina pectoris and myocardial infarction characterized by insufficient blood supply to the heart muscle, infiltrative diseases such as amyloidosis and hemochromatosis, global or localized thickening (such as may occur in some cardiomyopathies or systemic hypertension), and abnormal communication between the heart chambers (e.g., atrial septal defect). For further discussion, see Braunwald, Heart Disease: a Textbook of Cardiovascular Medicine, 5th edition 1997, WB Saunders Company, Philadelphia PA (hereinafter Braunwald).

[0031] Cardiomyopathy: any disease or dysfunction of the myocardium (heart muscle). Cardiomyopathy may be inflammatory, metabolic, toxic, infiltrative, fibrogenic, hematologic, genetic, or unknown in origin. Cardiomyopathy is commonly classified into three groups based primarily on clinical and pathological features: (1) Dilated cardiomyopathy, a syndrome characterized by cardiac hypertrophy and systolic dysfunction of one or both ventricles; (2) hypertrophic cardiomyopathy, defined herein as (a) a generalized or localized increase in the thickness of either the ventricular wall or the ventricular septum, or (b) an increased susceptibility to a generalized or localized increase in the thickness of either the ventricular wall or the ventricular septum, which may occur, for example, in genetic disease, hypertension, or cardiac valvular dysfunction; or (3) Restrictive and infiltrative cardiomyopathies, a group of diseases in which the predominant clinical feature is usually impairment of the heart's ability to relax (diastolic dysfunction) and is often characterized by infiltration of the cardiac muscle with foreign substances such as amyloid fibrils, iron, or glycolipids.

[0032] See Wynne and Braunwald, The Cardiomyopathies and Myocarditises, Chapter 41 in Braunwald.

[0033] Enrichment: A process in which the ratio of the amount of a desired component, such as nanovesicles, present in a mixture to the amount of other undesirable components in that mixture is higher after the enrichment process compared to before the enrichment process.

[0034] Extracellular Matrix (ECM): A complex mixture of structural and functional biomolecules and / or biopolymers, including but not limited to structural proteins, specialized proteins, proteoglycans, glycosaminoglycans, and growth factors, that surrounds and supports cells in tissues and is acellular unless otherwise specified. ECM preparations can be considered "decellularized" or "acellular," meaning that the cells have been removed from the source tissue by processes described herein and known in the art. "ECM-derived materials," such as "ECM-derived nanovesicles," "matrix-bound nanovesicles," "MBVs," or "ECM-derived nanovesicles," are nanovesicles prepared from natural ECM or from in vitro sources where ECM is produced by cultured cells. ECM-derived nanovesicles are defined below.

[0035] Fibrosis-related or fibrotic disease: a disease or disorder in which fibrosis is the primary pathological basis, outcome or symptom. Fibrosis, or scarring, is defined by the excessive accumulation of fibrous connective tissue (components of the extracellular matrix (ECM) such as collagen and fibronectin) in and around inflamed or damaged tissues, which can lead to permanent scarring, poor organ function, and ultimately death. Normal tissue repair can gradually evolve into an irreversible fibrotic response when tissue injury is severe or repetitive, or when the wound healing response itself becomes dysregulated. Fibrosis-related diseases include, for example, pathological scarring of the skin, such as keloids and hypertrophic scars; cirrhosis, such as cirrhosis of the liver or gallbladder; cardiac fibrosis; hepatic fibrosis; renal fibrosis; pulmonary fibrosis; bone marrow fibrosis; rheumatic heart disease; sclerosing peritonitis; glomerulosclerosis, scleroderma, mediastinal fibrosis, retroperitoneal fibrosis, and fibrosis of tendons and cartilage. Fibrosis can be the result of several factors. Examples include, just to name a few, inherited genetic disorders; persistent infections; repeated exposure to toxins, irritants or smoke; chronic autoimmune inflammation; minor human leukocyte antigen mismatch in transplantation; myocardial infarction; high serum cholesterol; obesity; and poorly controlled diabetes, as well as hypertension. Fibrosis can also be triggered by tissue injury. Regardless of the initiating event, however, a common feature of all fibrotic diseases is the activation of myofibroblasts, which produce ECM, a key mediator of fibrotic tissue remodeling. As used herein, "tissue injury" refers to any damage to tissue or deformation imposed on tissue such that changes occur in or to the tissue. Tissue injury includes cardiac tissue injury or lung tissue injury. Those skilled in the art will readily recognize that cardiac tissue injury can result from cardiac deformation or cardiac overload. Thus, generally, subjects in need of the methods and compositions presented herein include subjects with increased cardiac deformation and therefore increased risk of developing cardiac disease or disorder or fibrosis-related disease, such as cardiac fibrosis.Conditions that may lead to cardiac fibrosis include, but are not limited to, hypertrophic cardiomyopathy, sarcoidosis, myocarditis, chronic renal failure, toxic cardiomyopathy, surgery-mediated ischemia-reperfusion injury, acute and chronic organ rejection, aging, chronic hypertension, non-ischemic dilated cardiomyopathy, arrhythmia, atherosclerosis, HIV-associated cardiovascular disease, pulmonary hypertension.Conditions that may lead to pulmonary fibrosis include, but are not limited to, autoimmune diseases such as rheumatoid arthritis and Sjogren's syndrome, gastroesophageal reflux disease (GERD), sarcoidosis, smoking, exposure to asbestos or silica, exposure to rock and metal dust, viral infection, exposure to radiation, and certain medications.

[0036] Graft-versus-host disease (GVHD): A common serious complication of bone marrow or other tissue transplants in which donated immunologically competent lymphocytes react against the transplant recipient's own tissue. GVHD is a potential complication of any transplant that uses or contains stem cells from either related or unrelated donors.

[0037] There are two types of GVHD: acute and chronic. Acute GVHD appears within the first three months after transplant. Signs of acute GVHD include a reddish skin rash on the hands and feet, which can spread and become more severe, with peeling or skin blisters. Acute GVHD can also affect the stomach and intestines, where cramps, nausea, and diarrhea are present. Yellowing of the skin and eyes (jaundice) indicates that acute GVHD is affecting the liver. Chronic GVHD is ranked by its severity: stage / grade 1 is mild and stage / grade 4 is severe. Chronic GVHD develops three months or longer after transplant. Symptoms of chronic GVHD are similar to those of acute GVHD, but in addition, chronic GVHD can affect the mucous glands in the eyes, the salivary glands in the mouth, and the glands that lubricate the lining of the stomach and intestines.

[0038] Heart: A muscular organ of an animal that circulates blood. In mammals, the heart is composed of four chambers: the right atrium, the right ventricle, the left atrium, and the left ventricle. The right and left atrium are separated from each other by the interatrial septum, and the right and left ventricles are separated from each other by the interventricular septum. The right atrium and right ventricle are separated from each other by the tricuspid valve. The left atrium and left ventricle are separated from each other by the mitral valve.

[0039] The walls of the four chambers of the heart are composed of working muscle or myocardium, and connective tissue. The myocardium is composed of myocardial cells, which may also be referred to herein as cardiac cells, cardiac myocytes, cardiomyocytes, and / or cardiac fibers. Cardiomyocytes can be isolated from a subject and grown in vitro. The inner layer of myocardium closest to the cavity is referred to as the endocardium, and the outer layer of myocardium is referred to as the epicardium. The left ventricular cavity is connected in part to the interventricular septum and the left ventricular free wall. The left ventricular free wall is sometimes divided into regions, such as the anterior, posterior, and lateral walls; or the apex (the tip of the left ventricle, furthest from the atrium) and base (the part of the left ventricle closest to the atrium). Apical and basal are adjectives referring to corresponding regions of the heart.

[0040] In operation, the heart's primary role is to pump sufficient oxygenated blood to meet the metabolic needs of tissues and cells in a subject. The heart accomplishes this task with rhythmic and highly coordinated cycles of contraction and relaxation referred to as the cardiac cycle. For simplicity, the cardiac cycle can be divided into two broad categories: ventricular systole, which is the phase of the cardiac cycle in which the ventricles contract; and ventricular diastole, which is the phase of the cardiac cycle in which the ventricles relax. For a detailed discussion, see Opie, Chapter 12 in Braunwald. As used herein, the terms systole and diastole shall refer to ventricular systole and diastole, unless the context clearly dictates otherwise.

[0041] In normal circulation during health, the right atrium receives substantially deoxygenated blood from the body via the veins. During diastole, the right atrium contracts, causing blood to flow through the tricuspid valve into the right ventricle. The right ventricle fills with blood and then contracts (systole). The force of systole closes the tricuspid valve, causing blood to flow through the pulmonary valve into the pulmonary artery. The blood then goes to the lungs, where it releases carbon dioxide and picks up oxygen. The oxygenated blood returns to the heart via the pulmonary veins and enters the left atrium. During diastole, the left atrium contracts, causing blood to flow through the mitral valve into the left ventricle. The left ventricle fills with blood and then contracts, and the right ventricle contracts substantially simultaneously. The force of contraction closes the mitral valve, causing blood to flow through the aortic valve into the aorta. From the aorta, the oxygenated blood circulates to all tissues in the body, where oxygen is delivered to the cells. The deoxygenated blood then returns to the right atrium via the veins.

[0042] Within the cavity of the left ventricle are two large essentially cone-shaped extensions of the ventricular myocardium known as the anterior and posterior papillary muscles. These are connected to the ventricular surface of the mitral valve via thread-like extensions called chordae tendineae or tendons. One important role of the papillary muscles and tendons is to ensure that the mitral valve remains closed during ventricular systole. Another important role is to increase the force of contraction of the heart. Similarly, the right ventricle has papillary muscles and tendons that tether the tricuspid valve and increase the force of contraction.

[0043] Due to inherited or acquired disease processes and / or normal aging, cardiac muscle may develop dysfunction during either systole or diastole, or both. Dysfunction during systole is referred to as systolic dysfunction. Dysfunction during diastole is referred to as diastolic dysfunction. For a detailed discussion, see Opie Chapter 12, and Colucci et al. al., Chapter 13 in Braunwald.

[0044] Due to inherited or acquired disease processes and / or normal aging, dysfunction of one or more of the heart valves may occur.Valve dysfunction generally falls into two broad categories: stenosis, which is defined herein as incomplete opening of the valve during the cardiac cycle when the normally operating valve is substantially open; regurgitation, which is defined herein as incomplete closing of the valve during the cardiac cycle when the normally operating valve is substantially closed.Valve dysfunction also includes a condition known as mitral valve prolapse, in which the mitral valve leaflets prolapse backwards into the left atrium during ventricular systole.This condition may be associated with mild, moderate, or severe mitral regurgitation.

[0045] Valvular stenosis is generally characterized by a pressure gradient across the valve when it is open. Valvular insufficiency is generally characterized by retrograde ("backward") flow when the valve is closed. For example, mitral stenosis is characterized by a pressure gradient across the mitral valve near the end of ventricular diastole (a typical example of moderate mitral stenosis is a diastolic pressure of 5 mm in the left ventricle). (Hg, diastolic pressure in the left atrium 20mm Hg, pressure gradient of 15mm Hg). As another example, mitral regurgitation is characterized by a "backward" flow of blood from the left ventricle to the left atrium during ventricular systole.

[0046] Heart failure: Inability of the heart to provide sufficient oxygenated blood to meet the metabolic needs of tissues and cells in a subject. This is accompanied by circulatory congestion, such as congestion in the pulmonary or systemic veins. As used herein, the term heart failure encompasses heart failure of any cause, and is intended to encompass terms such as "congestive heart failure," "anterior heart failure," "posterior heart failure," "high output heart failure," and "low output heart failure." For a detailed discussion, see Chapters 13-17 in Braunwald.

[0047] Inhibition: The reduction of a disease or disorder, etc. Inhibition of a disease or disorder may result in a decrease in one or more signs or symptoms of the disease or disorder.

[0048] Interleukin (IL)-33: A member of the IL-1 superfamily of cytokines determined in part based on a molecular β-trefoil structure, a conserved structural type described for other IL-1 cytokines, including IL-1α, IL-1β, IL-1Ra, and IL-18. In this structure, the 12 β-strands of the β-trefoil are arranged in three pseudorepeats of four β-strand units, of which the first and last β-strands are antiparallel plates in a six-stranded β-barrel, while the second and third β-strands of each repeat form a β-hairpin located at the apex of the β-barrel. IL-33 binds to the high-affinity receptor family member ST2. IL-33 induces helper T cells, mast cells, eosinophils, and basophils to produce type 2 cytokines. Exemplary amino acid sequences of human IL-33 are provided in GENBANK® Accession Nos. NP_001186569.1, NP_001186570.1, NP_001300973.1, NP_001300974.1, and NP_001300975.1, available on April 5, 2018, all of which are incorporated by reference herein.

[0049] Isolated: An "isolated" biological component (such as a nucleic acid, protein, cell, or nanovesicle) is substantially separated or purified from other biological components that are naturally occurring components within the cells or ECM of an organism. "Isolated" nucleic acids and proteins include nucleic acids and proteins that have been purified by standard purification methods. Isolated nanovesicles have been removed from the fibrous material of the ECM. The term also encompasses nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids.

[0050] Lysyl oxidase (Lox): A copper-dependent enzyme that catalyzes the formation of aldehydes from lysine residues of collagen and elastin precursors. These aldehydes are highly reactive and undergo spontaneous chemical reactions with other lysyl oxidase-derived aldehyde residues or with unmodified lysine residues. In vivo, this leads to collagen and elastin cross-linking, which plays a role in stabilizing collagen fibrils and in the integrity and elasticity of mature elastin. Complex cross-links with different structures are formed in collagen (pyridinoline derived from three lysine residues) and elastin (desmosine derived from four lysine residues). Genes encoding Lox enzymes have been cloned from various organisms (Hamalainen et al., Genomics 11: 508, 1991; Trackman et al., Biochemistry 29: 4863, 1990; incorporated herein by reference). Residues 153-417 and 201-417 of the human lysyl oxidase sequence have been shown to be important for catalytic function. There are four Lox-like isoforms, designated LoxL1, LoxL2, LoxL3 and LoxL4.

[0051] Macrophage: a type of white blood cell that engulfs and breaks down cellular debris, foreign material, microorganisms, and cancer cells. In addition to their role in phagocytosis, these cells play important roles in both innate and adaptive immunity in development, tissue maintenance and repair, and in recruiting and influencing other cells, including immune cells such as lymphocytes. Macrophages can exist in many phenotypes, including those that have been designated M1 and M2. Macrophages that perform primarily pro-inflammatory functions are designated M1 macrophages (CD86+ / CD68+), while macrophages that reduce inflammation and also stimulate and regulate tissue repair are designated M2 macrophages (CD206+ / CD68+). Markers that identify the various phenotypes of macrophages vary between species. It should be noted that macrophage phenotypes are represented by a spectrum that spans between the extremes of M1 and M2. F4 / 80 (encoded by the adhesion G protein-coupled receptor E1 (ADGRE) gene) is a macrophage marker. See GENBANK® Accession Nos. NP_001243181.1, April 6, 2018, and NP_001965, March 5, 2018, both of which are incorporated herein by reference. It is disclosed herein that nanovesicles maintain expression of CD68 and CD11b on macrophages in a subject.

[0052] MicroRNA: Small non-coding RNAs, about 17 to about 25 nucleotide bases long, that post-transcriptionally regulate gene expression, typically by suppressing translation of target mRNAs. miRNAs can function as negative regulators, and thus high abundance of a particular miRNA correlates with low levels of target gene expression. There are three forms of miRNAs: primary miRNAs (pri-miRNAs), immature miRNAs (pre-miRNAs), and mature miRNAs. Primary miRNAs (pri-miRNAs) are expressed as stem-loop structured transcripts of about several hundred bases to more than 1 kb. Pri-miRNA transcripts are cleaved in the nucleus by an RNase II endonuclease called Drosha, which cleaves both strands of the stem near the base of the stem loop. Drosha cleaves the RNA duplex in a staggered fashion, leaving a 5' phosphate and a two-nucleotide overhang at the 3' end. The cleavage product, immature miRNA (pre-miRNA), is about 60 to about 110 nucleotides long and has a hairpin structure formed in a fold-back manner. Pre-miRNA is transported from the nucleus to the cytoplasm by Ran-GTP and exportin-5. In the cytoplasm, pre-miRNA is further processed by another RNase II endonuclease called Dicer. Dicer recognizes the 5' phosphate and 3' overhang and cleaves the loop at the stem-loop junction to form the miRNA duplex. The miRNA duplex binds to the RNA-induced silencing complex (RISC), where the antisense strand is preferentially degraded and the sense strand mature miRNA directs RISC to its target site. Mature miRNA is the biologically active form of miRNA and is about 17 to about 25 nucleotides long.

[0053] Myoblast: a muscle cell that has not fused with other myoblasts to form myofibrils or to existing myofibrils.

[0054] Nanovesicles: Extracellular vesicles that are nanoparticles with a diameter of about 10 to about 1,000 nm. Nanovesicles are lipid membrane-bound particles that carry biologically active signaling molecules (e.g., microRNA, proteins) among other molecules. In general, nanovesicles are limited by a lipid bilayer and can encapsulate and / or embed biomolecules in the bilayer. Thus, nanovesicles contain a lumen surrounded by a plasma membrane. Different types of vesicles can be distinguished based on their diameter, intracellular origin, density, shape, sedimentation rate, lipid composition, protein markers, nucleic acid content and origin, such as whether they are derived from the extracellular matrix or secreted. Nanovesicles can be identified by their origin, protein content and / or miR content, for example, matrix-bound nanovesicles derived from the ECM (see above).

[0055] "Exosomes" are membranous vesicles secreted by cells, ranging in diameter from 10 to 150 nm. Generally, late endosomes or multivesicular bodies contain intraluminal vesicles formed by inward budding and cleavage of vesicles from the defined endosomal membrane into these enclosed vesicles. Then, upon fusion with the plasma membrane, these intraluminal vesicles are released from the multivesicular body lumen during exocytosis into the extracellular environment, typically body fluids such as blood, cerebrospinal fluid or saliva. Exosomes arise within cells when segments of the membrane invaginate and are taken up by endocytosis. The internalized segments, which are broken down into smaller vesicles and eventually expelled from the cell, contain proteins and RNA molecules such as mRNA and miRNA. Exosomes derived from plasma are largely devoid of ribosomal RNA. Exosomes derived from the extracellular matrix contain specific miRNA and protein components and have been shown to be present in virtually every body fluid, such as blood, urine, saliva, semen, and cerebrospinal fluid. Exosomes can express CD11c and CD63, and thus, + and CD63 + It is possible that exosomes do not have high levels of lysyl oxidase on their surface.

[0056] "ECM-derived nanovesicles", "matrix-bound nanovesicles", "MBVs" or "ECM-derived nanovesicles" all refer to the same membrane-bound particles, ranging in size from 10 nm to 1000 nm, present in the extracellular matrix, and containing biologically active signaling molecules such as proteins, lipids, nucleic acids, growth factors and cytokines that influence cell behavior. The terms are interchangeable and refer to the same vesicles. These MBVs are embedded in and bound to the ECM, not simply attached to a surface. These MBVs are resistant to harsh isolation conditions such as freeze-thawing, and digestion with proteases such as pepsin, elastase, hyaluronidase, proteinase K, and collagenase, and detergent digestion. Generally, these MBVs are enriched for, among others, miR-145, and optionally miR-181, miR-143, and miR-125. These MBVs either do not express CD63 or CD81 or express these markers at barely detectable levels (CD63 lo CD81 lo ). MBVs contain lysyl oxidase (Lox) on their surface. ECM can be tissue-derived, produced by cells in culture, or purchased from commercial sources. MBVs are distinct from exosomes.

[0057] Organ or graft rejection: functional and structural deterioration of an organ that results from an active immune response mounted by the recipient and is independent of non-immunologic causes of organ dysfunction.

[0058] Pharmaceutically acceptable carriers: The pharma- ceutically acceptable carriers useful in the present invention are conventional. Remington's Pharmaceutical Sciences, by EW Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975) describe compositions and formulations suitable for pharmaceutical delivery of the fusion proteins disclosed herein.

[0059] Generally, the nature of the carrier will depend on the particular mode of administration used. For example, parenteral formulations usually contain injection fluids that contain pharma- ceutically and physiologically acceptable fluids as vehicles, such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol, etc. For solid compositions (e.g., in the form of powder, pill, tablet, or capsule), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically neutral carriers, the pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents, such as, for example, sodium acetate or sorbitan monolaurate.

[0060] Pharmaceutical agent: A chemical compound or composition that can produce a desired therapeutic or prophylactic effect when properly administered to a subject or cell. "Incubating" includes a sufficient time for the drug to interact with the cell. "Contacting" includes incubating an agent such as an exosome, miRNA, or a nucleic acid encoding miRNA with the cell in solid or liquid form.

[0061] Polynucleotide: A nucleic acid sequence of any length (e.g., a linear sequence, etc.). Thus, polynucleotide includes oligonucleotides, including gene sequences found in chromosomes. An "oligonucleotide" is a plurality of linked nucleotides linked by native phosphodiester bonds. An oligonucleotide is a polynucleotide between 6 and 300 nucleotides in length. An oligonucleotide analog refers to a moiety that functions similarly to an oligonucleotide, but has a non-naturally occurring portion. For example, an oligonucleotide analog may contain a non-naturally occurring portion, such as modified sugar moieties or inter-sugar linkages, e.g., phosphorothioate oligodeoxynucleotides. Functional analogs of naturally occurring polynucleotides can bind to RNA or DNA, and include peptide nucleic acid (PNA) molecules.

[0062] Purified: The term "purified" is intended as a relative term, not an absolute purity. Thus, for example, a purified nucleic acid molecule preparation is one in which the nucleic referred to in the preparation is more pure than the nucleic in its natural environment in a cell. For example, a preparation of nucleic acid is purified such that the nucleic acid is at least 50% of the total protein content of the preparation. Similarly, a purified exosome preparation is one in which the exosomes in the preparation are more pure than the exosomes in the environment containing the microvesicles and cells in which the exosomes reside. A purified population of nucleic acids or exosomes is greater than about 90% pure, greater than about 91%, greater than about 92%, greater than about 93%, greater than about 94%, greater than about 95%, greater than about 96%, greater than about 97%, greater than about 98%, greater than about 99% or 100% free of other nucleic acids or cellular components, respectively.

[0063] Preventing or Treating a Disease: "Preventing" a disease refers to inhibiting the onset of the disease in a person known to have a predisposition to the disease, such as, for example, glaucoma. Examples of people known to have a predisposition are those who have a family history of the disease or who have been exposed to factors that predispose the subject to the condition. "Treatment" refers to a therapeutic intervention that reverses the signs or symptoms of a disease or pathological condition after it has begun to develop.

[0064] ST2: A member of the interleukin 1 receptor family. ST2, also known as ILR1RL1, is also a member of the Toll-like receptor superfamily based on the function of its intracellular TIR domain, while the extracellular region is composed of immunoglobulin domains.

[0065] ST2 protein has two isoforms, which are directly related to the progression of cardiac disease: a soluble form (called soluble ST2 or sST2) and a membrane-bound receptor form (called ST2 receptor or ST2L). When the myocardium stretches, the ST2 gene is upregulated, thereby increasing the concentration of circulating soluble ST2. The ligand for ST2 is IL-33.

[0066] Binding of IL-33 to the ST2 receptor in response to cardiac disease or injury, such as an ischemic event, elicits a cardioprotective effect, resulting in the preservation of cardiac function. This cardioprotective IL-33 signal is counterbalanced by the levels of soluble ST2, which binds to IL-33 and makes it unavailable to the ST2 receptor for cardioprotective signaling. As a result, the heart is exposed to greater stress in the presence of high levels of soluble ST2.

[0067] Subject: Human and non-human animals, including all vertebrates, such as mammals and non-mammals, such as non-human primates, mice, rabbits, sheep, dogs, cats, horses, cows, chickens, amphibians, and reptiles. In many embodiments of the described methods, the subject is a human.

[0068] Therapeutically effective amount: An amount of a particular substance, such as MBV, sufficient to achieve a desired effect in a treated subject. When administered to a subject, a dosage is generally used that achieves a concentration in the target tissue (e.g., in bone) that has been shown to achieve the desired in vitro effect.

[0069] Transplantation: The movement of tissues, cells, or organs, or parts thereof, from one subject to another, from one subject to another part of the same subject, or from one subject to the same part of the same subject. In one embodiment, transplantation of a solid organ, such as the heart, kidney, skin, pancreas, or lung, involves removing the solid organ from one subject and introducing the solid organ into another subject.

[0070] Allografts or xenografts are transplants from one individual to another, where the individuals have genes at one or more loci that are not identical in sequence in the two individuals.Allografts can be performed between two individuals of the same species that are genetically different, or between two individuals of different species.Autografts are transplants of tissue, cells, or parts thereof from one location to another within the same individual, or transplants of tissue or parts thereof from one individual to another when the two individuals are genetically identical.

[0071] "Implantation" refers to the placement of a biocompatible substrate into a subject in need thereof.

[0072] Treating, treatment, and therapy: Any success or indication of success regarding the attenuation or reversal of an injury, medical condition, or condition, including any objective or subjective parameter such as relief, remission, reduction in symptoms, or the condition becoming more tolerable to the patient, a slowing of the rate of degeneration or decline, a less debilitating end point of degeneration, improved physical or mental well-being of the subject, or improved vision. Treatment can be assessed by objective or subjective parameters, including the results of a physical examination, a neurological examination, or a psychiatric evaluation.

[0073] Unless otherwise explained, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The singular terms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. Thus, "comprising A or B" is intended to include "and" unless the context clearly indicates otherwise. "A" or "B" means A, B, or A and B. It should be further understood that all base or amino acid sizes and all molecular weight or molecular mass values ​​given for nucleic acids or polypeptides are approximate and are provided for illustration purposes. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. Unless otherwise specified, "about" means within 5 percent. In case of conflict, the present specification, including explanations of terms, shall control. Additionally, the materials, methods, and examples are merely illustrative and not limiting. Nanovesicles derived from extracellular matrix (ECM)

[0074] Nanovesicles derived from ECM (also referred to as matrix-bound nanovesicles, MBVs) are disclosed in PCT Publication No. WO2017 / 151862, which is incorporated herein by reference. It is disclosed that the nanovesicles are embedded in extracellular matrix. These MBVs can be isolated and are biologically active. Therefore, these MBVs can be used alone or with another ECM for therapeutic purposes. These MBVs can be used alone or with another ECM for biological scaffolds. It is disclosed herein that MBVs contain IL-33 and are useful for treating cardiac diseases and disorders and fibrotic diseases and disorders. In some non-limiting examples, the nanovesicles maintain the expression of CD68 and CD11b on macrophages in a subject.

[0075] Extracellular matrix is ​​a complex mixture of structural and functional biomolecules and / or biopolymers, including, but not limited to, structural proteins, specialized proteins, proteoglycans, glycosaminoglycans, and growth factors, that surround and support cells in mammalian tissues and are acellular unless otherwise specified. In general, the disclosed MBVs are embedded in any type of extracellular matrix (ECM) and can be isolated from the location. Thus, MBVs are not separably present on the surface of the ECM and are not exosomes.

[0076] Extracellular matrices may be prepared by any of the methods described, for example and without limitation, in U.S. Pat. Nos. 4,902,508; 4,956,178; 5,281,422; 5,352,463; 5,372,821; 5,554,389; 5,573,784; 5,645,860; 5,771,969; 5,753,267; 5,762,966; 5,866,414; 6,099,567; 6,485, No. 723; U.S. Patent No. 6,576,265; U.S. Patent No. 6,579,538; U.S. Patent No. 6,696,270; U.S. Patent No. 6,783,776; U.S. Patent No. 6,793,939; U.S. Patent No. 6,849,273; U.S. Patent No. 6,852,339; U.S. Patent No. 6,861,074; U.S. Patent No. 6,887,495; U.S. Patent No. 6,890,562; U.S. Patent No. 6,890,563; U.S. Patent No. 6,890,564; and U.S. Patent No. 6,893,666; each of which is incorporated by reference in its entirety. However, ECM can be made from any tissue or from any in vitro source, where the ECM is produced by cultured cells and includes one or more polymeric components (constituents) of native ECM. ECM preparations are considered to be "decellularized" or "acellular," meaning that the cells have been removed from the source tissue or culture.

[0077] In some embodiments, the ECM is isolated from a vertebrate, for example, a mammalian vertebrate, including, but not limited to, human, monkey, pig, cow, sheep, etc. The ECM can be derived from any organ or tissue, including, but not limited to, the bladder, intestine, liver, heart, esophagus, spleen, stomach, and dermis. In a specific, non-limiting example, the extracellular matrix is ​​isolated from esophageal tissue, bladder, small intestinal submucosa, dermis, umbilical cord, pericardium, cardiac tissue, or skeletal muscle. The ECM can include any part or tissue from an organ, including, but not limited to, the submucosa, epithelial basement membrane, lamina propria, etc. In one non-limiting embodiment, the ECM is isolated from the bladder. The ECM can be made from tumor tissue.

[0078] The ECM may or may not include a basement membrane. In another non-limiting embodiment, the ECM includes at least a portion of a basement membrane. The ECM material may or may not retain some of the cellular elements that make up the original tissue, such as capillary endothelial cells or fibrocytes. In some embodiments, the ECM contains both basement membrane and non-basement membrane surfaces.

[0079] In one non-limiting embodiment, the ECM is harvested from a porcine bladder (also known as urinary bladder matrix or UBM). Briefly, the ECM is prepared by removing bladder tissue from a mammal, such as a pig, and trimming off any outer connective tissue, including residual adipose tissue. Any residual urine is removed by repeated washing with tap water. The tissue is first delaminated by immersing it in a de-epithelialization solution, such as, but not limited to, hypertonic saline (e.g., 1.0 N saline), for a period ranging from 10 minutes to 4 hours. Exposure to the hypertonic saline solution removes the epithelial cells from the underlying basement membrane. Optionally, a calcium chelator can be added to the saline solution. The remaining tissue after the initial delamination procedure includes the epithelial basement membrane and the tissue layer abluminal to the epithelial basement membrane. The relatively fragile epithelial basement membrane is constantly damaged and is removed by any mechanical peeling against the luminal surface. The tissue is then subjected to further processing to remove most of the abluminal tissue but maintain the epithelial basement membrane and lamina propria. The outer serosa, adventitia, muscularis mucosa, submucosa and most of the muscularis mucosa are removed from the remaining epithelial-free tissue by mechanical peeling or by a combination of enzymatic treatment (e.g., using trypsin or collagenase), followed by hydration and peeling. Mechanical removal of these tissues is accomplished, for example and without limitation, by removing the mesenteric tissue with Adson-Brown forceps and Metzenbaum scissors, and wiping off the muscularis and submucosa using a longitudinal wiping motion with a scalpel handle or other rigid object wrapped in moist gauze. Automated robotic procedures involving cutting blades, lasers and other tissue separation methods are also contemplated. After removal of these tissues, the resulting ECM consists primarily of the epithelial basement membrane and the underlying lamina propria.

[0080] In another embodiment, the ECM is prepared by peeling porcine bladder tissue using a scalpel handle and a moistened gauze wiping motion in a longitudinal direction to remove the outer layers, including both the serosa and muscularis. After inverting the tissue segment, the luminal portion of the mucosa is delaminated from the underlying tissue using the same wiping motion. Care is taken not to puncture the submucosa. The ECM obtained after removing these tissues consists mainly of the submucosa (see FIG. 2 of U.S. Pat. No. 9,277,999, incorporated herein by reference).

[0081] ECM can also be prepared as a powder. Such powder can be made according to the method of Gilbert et al., Biomaterials 26 (2005) 1431-1435, the entirety of which is incorporated herein by reference. For example, UBM sheets can be freeze-dried and then cut into small sheets for immersion in liquid nitrogen. The snap-frozen material can then be finely ground so that the particles are small enough to enter a rotary knife mill, thereby pulverizing the ECM. Similarly, the material can be broken into uniformly sized particles by precipitating NaCl within the ECM tissue, which can then be snap-frozen, freeze-dried, and pulverized.

[0082] In one non-limiting embodiment, the ECM is derived from small intestinal submucosa or SIS. Commercially available preparations include, but are not limited to, SURGISIS™, SURGISIS-ES™, STRATASIS™, and STRATASIS-ES™ (Cook Urological Inc.; Indianapolis, Ind.) and GRAFTPATCH™ (Organogenesis Inc.; Canton Mass.). In another non-limiting embodiment, the ECM is derived from the dermis. Commercially available preparations include, but are not limited to, PELVICOL™ (sold as PERMACOL™ in Europe; Bard, Covington, Ga.), REPLIFORM™ (Microvasive; Boston, Mass.), and ALLODERM™ (LifeCell; Branchburg, NJ). In another embodiment, the ECM is derived from the urinary bladder. Commercially available preparations include, but are not limited to, UBM (ACell Corporation; Jessup, Md.).

[0083] MBVs can be extracted (released) from the extracellular matrix using methods disclosed below. In some embodiments, the ECM is digested with enzymes such as pepsin, collagenase, elastase, hyaluronidase, or proteinase K to isolate the MBVs. In other embodiments, the MBVs are released and separated from the ECM by altering the pH using solutions such as glycine HCL, citric acid, ammonium hydroxide, etc., by the use of chelating agents such as, but not limited to, EDTA, EGTA, by ionic strength and / or chaotropic effects using salts such as, but not limited to, potassium chloride (KCl), sodium chloride, magnesium chloride, sodium iodide, sodium thiocyanate, or by exposing the ECM to denaturing conditions such as guanidine HCl or urea.

[0084] In certain instances, MBVs are prepared following digestion of the ECM with enzymes such as pepsin, elastase, hyaluronidase, proteinase K, saline, or collagenase. The ECM can be subjected to freeze-thawing or mechanical degradation.

[0085] The disclosed MBVs contain IL-33. In some embodiments, the expression of CD63 and / or CD81 cannot be detected in the MBVs. Thus, the MBVs do not express CD63 and / or CD81. In certain examples, neither CD63 nor CD81 can be detected in the nanovesicles. In other embodiments, the MBVs have barely detectable levels of CD63 and CD81, such as detectable by Western blot. These MBVs do not express CD63. lo CD81 lo Those skilled in the art can, for example, detect CD63 using antibodies that specifically bind to CD63 and CD81. lo CD81 lo MBVs that are CD63 and CD81 can be easily identified. Low levels of these markers can be established using procedures such as fluorescence-activated cell sorting (FACS) and fluorescently labeled antibodies to determine thresholds for low and high amounts of CD63 and CD81. The disclosed MBVs are present in biological fluids and are therefore distinct from nanovesicles such as exosomes that may be transiently attached to the surface of ECM.

[0086] MBVs contain lysyl oxidase (Lox). In general, the Lox content of nanovesicles derived from ECM is higher than that of exosomes. Lox is expressed on the surface of MBVs. NanoLC MS / MS proteomics analysis can be used to detect Lox protein. Quantification of Lox can be performed as previously described (Hill RC, et al., Mol Cell Proteomics. 2015; 14 (4): 961-73).

[0087] In certain embodiments, the MBV comprises one or more miRNAs.In certain non-limiting examples, the MBV comprises one, two or all three of miR-143, miR-145 and miR-181.MiR-143, miR-145 and miR-181 are known in the art.

[0088] The miR-145 nucleic acid sequence is provided in MiRbase Accession No. MI0000461, which is incorporated herein by reference. The miR-145 nucleic acid sequence is CACCUUGUCCUCACGGUCCAGUUUUCCCAGGAAUCCCUUAGAUGCUAAGAUGGGGAUUCCUGGAAAUACUGUUCUUGAGGUCAUGGUU (SEQ ID NO: 1). The miR-181 nucleic acid sequence is provided in miRbase Accession No. MI0000269, which is incorporated herein by reference. The miR-181 nucleic acid sequence is AGAAGGGCUAUCAGGCCAGCCUUCAGAGGACUCCAAGGAACAUUCAACGCUGUCGGUGAGUUUGGGAUUUGAAAAAACCACUGACCGUUGACUGUACCUUGGGGUCCUUA (SEQ ID NO: 2). The miR-143 nucleic acid sequence is provided in NCBI Accession No. NR_029684.1, March 30, 2018, which is incorporated herein by reference. The miR-143 nucleic acid sequence is GCGCAGCGCC CUGUCUCCCA GCCUGAGGUG CAGUGCUGCA UCUCUGGUCA GUUGGGAGUC UGAGAUGAAG CACUGUAGCU CAGGAAGAGA GAAGUUGUUC UGCAGC (SEQ ID NO: 3).

[0089] In some embodiments, after administration, MBV maintains the expression of CD68 and CD11b in macrophages in subjects.In the disclosed experimental studies, macrophages treated with nanovesicles are mainly F4 / 80+Fizz1+, which shows M2 phenotype.Thus, in some embodiments, macrophages maintain M2 phenotype.

[0090] The MBV disclosed herein can be formulated into compositions for pharmaceutical delivery and used in bioscaffolds and devices. MBV is disclosed in PCT Publication No. WO2017 / 151862, which is incorporated herein by reference. Isolation of MBVs from the ECM

[0091] To make MBVs, ECM can be produced by any cell of interest or can be utilized from commercial sources. See above. MBVs can be made from the same species as the subject being treated or from a different species. In some embodiments, the methods include enzymatically digesting the ECM to make digested ECM. In certain embodiments, the ECM is digested with one or more of pepsin, elastase, hyaluronidase, collagenase, metalloproteinase, and / or proteinase K. In certain non-limiting examples, the ECM is digested with elastase and / or metalloproteinase only. In another non-limiting example, the ECM is not digested with collagenase and / or trypsin and / or proteinase K. In other embodiments, the ECM is treated with a detergent. In further embodiments, the method does not include the use of enzymes. In certain non-limiting examples, the method utilizes chaotropic agents, such as salts, such as potassium chloride, or ionic strength to isolate MBVs. In additional embodiments, the ECM can be engineered to increase MBV content prior to isolation of the MBVs.

[0092] In some embodiments, the ECM is digested with an enzyme. The ECM can be digested with an enzyme for about 12 to about 48 hours, such as, for example, about 12 to about 36 hours. The ECM can be digested with an enzyme for about 12, about 24, about 36, or about 48 hours. In one specific, non-limiting example, the ECM is digested with an enzyme at room temperature. However, digestion can be performed at about 4°C, or any temperature between about 4°C and 25°C. In general, the ECM is digested with an enzyme at any temperature for any length of time sufficient to remove collagen fibrils. The digestion process can vary depending on the tissue source. If necessary, the ECM is treated by freezing and thawing either before or after digestion with the enzyme. The ECM can be treated with detergents, including ionic and / or non-ionic detergents.

[0093] The digested ECM is then processed, for example by centrifugation, to isolate a fibril-free supernatant. In some embodiments, the digested ECM is centrifuged, for example, at about 300 to about 1000 g as a first step. Thus, the digested ECM can be centrifuged at about 400 g to about 750 g, for example, at about 400 g, about 450 g, about 500 g, or about 600 g. This centrifugation can be performed for about 10 to about 15 minutes, for example, for about 10 to about 12 minutes, for example, for about 10, about 11, about 12, about 14, about 14, or about 15 minutes. The supernatant containing the digested ECM is collected.

[0094] MBVs comprise Lox. In some embodiments, methods for isolating such MBVs include digesting extracellular matrix with elastase and / or metalloproteinase to produce digested extracellular matrix, centrifuging the digested extracellular matrix to remove collagen fibril remnants, thus producing a fibril-free supernatant, centrifuging the fibril-free supernatant to isolate solids, and suspending the solids in a carrier.

[0095] In some embodiments, the digested ECM can also be centrifuged at about 2000 g to about 3000 g as a second step. Thus, the digested ECM can be centrifuged at about 2,500 g to about 3,000 g, such as about 2,000 g, 2,500 g, 2,750 g or 3,000 g. This centrifugation can be carried out for about 20 to about 30 minutes, such as for about 20 to about 25 minutes, such as for about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29 or about 30 minutes. The supernatant containing the digested ECM is collected.

[0096] In additional embodiments, the digested ECM can be centrifuged at about 10,000 to about 15,000 g as a third step. Thus, the digested ECM can be centrifuged at about 10,000 g to about 12,500 g, for example, about 10,000 g, 11,000 g or 12,000 g. This centrifugation can be carried out for about 25 to about 40 minutes, for example, for about 25 to about 30 minutes, for example, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39 or about 40 minutes. The supernatant containing the digested ECM is collected.

[0097] One, two, or all three of these centrifugation steps can be used independently. In some embodiments, all three centrifugation steps are used. The centrifugation steps can be repeated, for example, two, three, four, or five times. In one embodiment, all three centrifugation steps are repeated three times.

[0098] In some embodiments, the digested ECM is centrifuged at about 500g for about 10 minutes, at about 2,500g for about 20 minutes, and / or at about 10,000g for about 30 minutes. These step(s), for example, all three steps, can be repeated two, three, four, or five times, for example, three times. Thus, in one non-limiting example, the digested ECM is centrifuged at about 500g for about 10 minutes, at about 2,500g for about 20 minutes, and at about 10,000g for about 30 minutes. These three steps are repeated three times. In this way, a fibril-free supernatant is produced.

[0099] The fibril-free supernatant is then centrifuged to isolate MBVs. In some embodiments, the fibril-free supernatant is centrifuged at about 100,000 g to about 150,000 g. Thus, the fibril-free supernatant is centrifuged at about 100,000 g to about 125,000 g, for example, about 100,000 g, about 105,000 g, about 110,000 g, about 115,000 g, or about 120,000 g. This centrifugation can be carried out for about 60 to about 90 minutes, for example, about 70 to about 80 minutes, for example, about 60, about 65, about 70, about 75, about 80, about 85, or about 90 minutes. In a non-limiting example, the fibril-free supernatant is centrifuged at about 100,000 g for about 70 minutes. The solid matter, which is the MBVs, is collected. These MBVs can then be resuspended in any desired carrier, such as, but not limited to, a buffer.

[0100] In further embodiments, the ECM is not digested with an enzyme. In these methods, the ECM is suspended in an isotonic salt solution, such as phosphate buffered saline. Salt is then added to the suspension such that the final concentration of salt is greater than about 0.1M. The concentration can be, for example, up to about 3M, such as about 0.1M salt to about 3M, or about 0.1M to about 2M. The salt can be, for example, about 0.1M, 0.15M, 0.2M, 0.3M, 0.4M, 0.7M, 0.6M, 0.7M, 0.8M, 0.9M, 1.0M, 1.1M, 1.2M, 1.3M, 1.4M, 1.5M, 1.6M, 1.7M, 1.8M, 1.9M, or 2M. In some non-limiting examples, the salt is potassium chloride, sodium chloride, or magnesium chloride. In other embodiments, the salt is sodium chloride, magnesium chloride, sodium iodide, sodium thiocyanate, a sodium salt, a lithium salt, a cesium salt, or a calcium salt.

[0101] In some embodiments, the ECM is suspended in the salt solution for about 10 minutes to about 2 hours, such as about 15 minutes to about 1 hour, about 30 minutes to about 1 hour, or about 45 minutes to about 1 hour. The ECM can be suspended in the salt solution for about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, or 120 minutes. The ECM can be suspended in the salt solution at a temperature of 4°C to about 50°C, such as, but not limited to, about 4°C to about 25°C or about 4°C to about 37°C. In certain non-limiting examples, the ECM is suspended in the salt solution at about 4°C. In other certain non-limiting examples, the ECM is suspended in the salt solution at about 22°C or about 25°C (room temperature). In another non-limiting example, the ECM is suspended in saline at about 37°C.

[0102] In some embodiments, the method includes incubating the extracellular matrix at a salt concentration greater than about 0.4 M, centrifuging the digested extracellular matrix to remove collagen fibril remnants, isolating the supernatant, centrifuging the supernatant to isolate solids, and suspending the solids in a carrier, thereby isolating the MBVs from the extracellular matrix.

[0103] After incubation in the salt solution, the ECM is centrifuged to remove collagen fibrils. In some embodiments, the digested ECM can be centrifuged at about 2000 g to about 5000 g. Thus, the digested ECM can be centrifuged at about 2,500 g to about 4,500 g, such as about 2,500 g, about 3,000 g, 3,500, about 4,000 g, or about 4,500 g. In a specific, non-limiting example, the centrifugation is performed at about 3,500 g. This centrifugation can be performed for about 20 to about 40 minutes, such as about 25 to about 35 minutes, such as about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30 minutes, about 31, about 32, about 33, about 34, or about 35 minutes. The supernatant is then collected.

[0104] In additional embodiments, the supernatant can then be centrifuged at about 100,000 to about 150,000 g as a third step. Thus, the digested ECM can be centrifuged at about 100,000 g to about 125,000 g, for example, at about 100,000 g, 110,000 g or 120,000 g. This centrifugation can be carried out for about 30 minutes to about 2.5 hours, for example, for about 1 hour to about 3 hours, for example, for about 30 minutes, about 45 minutes, about 60 minutes, about 90 minutes, or about 120 minutes (2 hours). The solids can be collected and suspended in a solution such as buffered saline, thereby isolating the MBVs.

[0105] In yet another embodiment, the ECM is suspended in an isotonic buffered saline solution, such as, but not limited to, phosphate buffered saline. Large particles can be removed using centrifugation or other methods (see below). Ultrafiltration is then used to isolate MBV from the ECM, with particles between about 10 nm and about 10,000 nm, for example, between about 10 and about 1,000 nm, for example, between about 10 nm and about 300 nm.

[0106] In a specific, non-limiting example, the isotonic buffered saline solution has a total salt concentration of about 0.164 mM and a pH of about 7.2 to about 7.4. In some embodiments, the isotonic buffered saline solution contains 0.002 M KCl to about 0.164 M KCL, for example, about 0.0027 M KCl (concentration of KCL in phosphate buffered saline). The suspension is then processed by ultracentrifugation.

[0107] After incubation in the isotonic buffered salt solution, the ECM is centrifuged to remove collagen fibrils. In some embodiments, the digested ECM can be centrifuged at about 2000 g to about 5000 g. Thus, the digested ECM can be centrifuged at about 2,500 g to about 4,500 g, such as about 2,500 g, about 3,000 g, 3,500, about 4,000 g, or about 4,500 g. In one specific, non-limiting example, centrifugation is performed at about 3,500 g. This centrifugation can be performed for about 20 to about 40 minutes, such as for about 25 to about 35 minutes, such as for about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30 minutes, about 31, about 32, about 33, about 34, or about 35 minutes.

[0108] Microfiltration and centrifugation can be used and combined to remove high molecular weight materials from suspension. In one embodiment, microfiltration is used to remove large molecular weight materials, such as those larger than 200 nm. In another embodiment, centrifugation is used to remove large size materials. In a third embodiment, both microfiltration and ultracentrifugation are used to remove high molecular weight materials. High molecular weight materials, such as materials larger than about 10,000 nm, larger than about 1,000 nm, larger than about 500 nm, or larger than about 300 nm, are removed from suspended ECM.

[0109] The effluent or supernatant of the microfiltration is then subjected to ultrafiltration. Thus, the effluent containing particles less than about 10,000 nm, less than about 1,000 nm, less than about 500 nm, or less than about 300 nm is collected and utilized. The effluent is then subjected to ultrafiltration using a membrane with a molecular weight cutoff (MWCO) of 3,000 to 100,000. In the examples, a 100,000 MWCO was used. Methods for Treating a Subject

[0110] The disclosed methods include administering to a subject a therapeutically effective amount of MBV containing IL-33, thereby treating the subject and inhibiting a disease or disorder in the subject. In some embodiments, the method prevents the disease or disorder.

[0111] In one non-limiting embodiment, the disease or disorder is fibrosis of an organ or tissue. For example, the fibrosis is liver cirrhosis, pulmonary fibrosis, cardiac fibrosis, mediastinal fibrosis, arthrofibrosis, bone marrow fibrosis, nephrogenic systemic fibrosis, keloid fibrosis, scleroderma fibrosis, renal fibrosis, lymphoid tissue fibrosis, arterial fibrosis, capillary fibrosis, vascular fibrosis, or pancreatic fibrosis. In one embodiment, the fibrosis is pulmonary fibrosis. The fibrosis may include idiopathic pulmonary fibrosis, pulmonary fibrosis resulting from disease or exposure to environmental toxins, or radiation-induced pulmonary fibrosis. In yet another embodiment, the fibrosis is cardiac fibrosis. The cardiac fibrosis may include reactive interstitial fibrosis, replacement fibrosis, infiltrative fibrosis, or endomyocardial fibrosis. In one embodiment, the fibrosis is associated with acute or chronic organ rejection. For example, in one embodiment, the fibrosis is cardiac fibrosis associated with acute or chronic rejection of a transplanted heart.

[0112] In another non-limiting embodiment, the disease or disorder is a cardiac disease or disorder. In one embodiment, the disease or disorder is a cardiac disease or disorder that is not myocardial infarction. In another embodiment, the cardiac disease or disorder is a cardiac disease or disorder that is not myocardial ischemia. In yet another embodiment, the cardiac disease or disorder is a cardiac disease or disorder that is not myocardial infarction or myocardial ischemia. In one embodiment, the disease or disorder is myocardial infarction or myocardial ischemia. In one embodiment, the cardiac disease or disorder is selected from myocardial infarction, myocardial ischemia, acute coronary syndrome, chronic stable angina, unstable angina, angioplasty, transient ischemic attack, ischemic reperfusion injury, claudication, vascular occlusion, arteriosclerosis, heart failure, chronic heart failure, acute decompensated heart failure, cardiac hypertrophy, aortic valve disease, aortic or mitral stenosis, cardiomyopathy, atrial fibrillation, cardiac arrhythmia, and pericardial disease. In one embodiment, the cardiac disease or disorder is selected from acute coronary syndrome, chronic stable angina, unstable angina, angioplasty, transient ischemic attack, ischemic reperfusion injury, claudication, vascular occlusion, arteriosclerosis, heart failure, chronic heart failure, acute decompensated heart failure, cardiac hypertrophy, aortic valve disease, aortic or mitral stenosis, cardiomyopathy, atrial fibrillation, cardiac arrhythmia, and pericardial disease. In yet another embodiment, the disease is acute coronary syndrome, chronic stable angina, unstable angina, angioplasty, transient ischemic attack, claudication, vascular occlusion, arteriosclerosis, heart failure, cardiac hypertrophy, and cardiomyopathy. In yet another embodiment, the disease is myocardial infarction, myocardial ischemia, acute coronary syndrome, chronic stable angina, unstable angina, angioplasty, transient ischemic attack, claudication, vascular occlusion, arteriosclerosis, heart failure, cardiac hypertrophy, and cardiomyopathy.

[0113] In yet another non-limiting embodiment, the disease or disorder is solid organ graft rejection. In one embodiment, the transplanted solid organ is the liver, kidney, heart, skin, lung, pancreas, or intestine. In one embodiment, the transplanted solid organ is the lung. In another embodiment, the transplanted solid organ is the heart. In one embodiment, the graft rejection is chronic organ graft rejection. In another embodiment, the graft rejection is acute organ graft rejection.

[0114] In yet another non-limiting embodiment, the disease or disorder is rejection of transplanted tissue, e.g., allografts of heart valves, blood vessels, bones, corneas, or composite tissues including the face, hands, or fingers.

[0115] Subjects with or at risk of developing diseases or disorders such as heart disease or disorders, solid organ transplant rejection, or organ or tissue fibrosis can be treated by increasing IL-33 signaling through membrane-bound ST2.See US Patent Application Publication No. 2008 / 0003199A1, which is incorporated herein by reference.It is disclosed herein that MBVs contain IL-33 and can therefore be used for these subjects.The use of MBVs containing membrane-encapsulated IL-33 prevents IL-33 from binding to ST2 receptor, and reduces the induction of proinflammatory kinase cascade.In some non-limiting examples, nanovesicles maintain the expression of CD68 and CD11b on macrophages in subjects.

[0116] IL-33 is stably present in the lumen of MBVs, and IL-33 encapsulated within MBVs bypasses the classical ST2 receptor signaling pathway to direct immune cell differentiation and / or function after MBV endocytosis.

[0117] In some embodiments, subjects can be treated using the disclosed methods, where the subjects have or are at risk of developing cardiac disease or disorder, including subjects who have already been diagnosed (using the methods presented herein and / or known in the art) as having cardiac disease or disorder, as well as subjects who are considered to be at risk of suffering from cardiac disease or disorder at some point in the future. This latter group of subjects includes subjects who are at risk of suffering from cardiovascular events. In further embodiments, the cardiac disease is not myocardial infarction or myocardial ischemia. In other embodiments, the disorder is cardiac fibrosis and / or heart failure. In one embodiment, the disorder is heart failure.

[0118] The method and composition are useful in the acute, chronic and preventive treatment of any cardiac disease or disorder.As used herein, acute treatment refers to the treatment of a subject who currently has a particular disease or disorder, such as an ischemic event.Preventive treatment refers to the treatment of a subject who is at risk of having a disease or disorder, but does not currently have the disease or disorder or experience symptoms thereof.When a subject who needs treatment has a particular cardiac disease or disorder, treating the cardiac disease or disorder refers to improving, reducing or eliminating the disease or disorder or one or more symptoms resulting from the disease or disorder.When a subject who needs treatment is a subject who is at risk of developing a cardiac disease or disorder, treating the subject refers to reducing the subject's risk of developing the disease or disorder.

[0119] Disclosed herein is a method for preventing or treating graft-versus-host disease (GVHD).Therefore, subjects with GVHD or at risk of GVHD can be selected for treatment.GVHD can be acute or chronic.

[0120] In some embodiments, subjects who are recipients of transplanted organs, such as solid organ transplants, are treated. Examples of transplanted organs include solid organ transplants, including kidney, skin, liver, composite tissue allografts (CTAs; including those of face, hand, limb, penis, etc.) or heart. Kidney transplants account for approximately 60% of solid organ transplants, followed by liver transplants at 21%, heart at 8%, lung at 4%, and the remaining 7% are other organ transplants, such as pancreas and intestine. (OPTN / SRTR Annual Report 2004). The type of organ is not particularly limited and includes parenchymal organs such as heart, liver, kidney, pancreas, lung, and small intestine. However, the disclosed method is also applicable to transplants of heart valves, blood vessels, skin, bone, and cornea. Thus, subjects who have received any type of organ transplant can be selected for treatment. The transplant can be a solid organ transplant. The solid organ can be the heart. MBV can be administered at the time of transplantation or after the transplantation procedure, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days after transplantation. In some non-limiting examples, MBV can be administered directly to the graft.

[0121] A method is disclosed for suppressing rejection, such as acute or chronic rejection of solid organ transplantation. The type of rejection suppressed by the suppressor of the present invention is not particularly limited, but may be acute rejection, which is problematic in practical transplantation medicine. These rejections are pathological conditions in which allogeneic grafts are recognized as foreign antigens due to differences in major histocompatibility complexes (MHC), which determine tissue compatibility, and are therefore attacked through the activation of cytotoxic T cells and helper T cells of the recipient. Acute rejection generally occurs within 3 months of transplantation. However, rejection can also be recognized as cellular infiltration into allogeneic graft tissue 3 months or more after transplantation. The disclosed method is useful at any time point after transplantation, including within 3 months or after 3 months of transplantation. In some embodiments, the method improves the viability of transplanted organs by suppressing damage.

[0122] In yet another embodiment, the subject has or is at risk of having a fibrosis-related disease. Also provided is a method for reducing fibrosis using a therapeutically effective amount of MBV. Such a method can be performed in vitro or in vivo. As used herein, "contacting" refers to placing an agent such as MBV to directly interact with one or more cells, or indirectly, such that one or more cells are affected in some way as a result. When the method is performed in vivo, the subject is administered MBV in an amount effective to reduce fibrosis. In a further embodiment, the disclosed method increases the anatomically appropriate cells native to the tissue or organ in which fibrosis occurs.

[0123] In the case of cardiac fibrosis, MBV is administered to the subject in an amount effective to reduce fibrosis and / or increase cardiac muscle cells. Methods for assessing the reduction of native cell growth or fibrosis are readily apparent to those skilled in the art. Thus, subjects with or at risk of developing fibrosis-related diseases can also be treated by administering MBV. In certain non-limiting embodiments, methods for treating fibrosis are provided. These include, but are not limited to, liver cirrhosis, pulmonary fibrosis, cardiac fibrosis, mediastinal fibrosis, arthrofibrosis, bone marrow fibrosis, nephrogenic systemic fibrosis, keloid fibrosis, scleroderma fibrosis, renal fibrosis, lymphoid tissue fibrosis, arterial fibrosis, capillary fibrosis, vascular fibrosis, or pancreatic fibrosis. In certain non-limiting examples, the disorder is pulmonary fibrosis, such as interstitial pulmonary fibrosis or fibrosis induced by occupational exposure.

[0124] In some embodiments, for lung treatment, compositions containing MBV can be administered using inhalation preparations. These inhalation preparations can include aerosols, particles, and the like. In general, the particle size target for inhalation is about 1 μm or less so that the drug reaches the alveolar region of the lung for absorption. However, the particle size can be modified to adjust the deposition area in the lung. Thus, larger particles can be utilized (e.g., about 1 to about 5 μm in diameter, etc.) to achieve deposition in the respiratory bronchioles and air spaces.

[0125] For administration by inhalation, the composition can be conveniently delivered in the form of aerosol spray presentation from pressurized pack or nebulizer, using suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.In the case of pressurized aerosol, dosage unit can be determined by providing a valve to deliver a metered amount.Capsules and cartridges for use in inhaler or insufflator can be formulated, containing a powder mix of compound and suitable powder base, such as lactose and starch.

[0126] In another embodiment, MBV is administered in combination with a therapeutically effective amount of an additional agent, such as an anti-inflammatory agent, a bronchodilator, an enzyme, an expectorant, a leukotriene antagonist, a leukotriene formation inhibitor, or a mast cell stabilizer, either simultaneously, e.g., in a single formulation, or sequentially.

[0127] The effect of treatment can be measured by monitoring pulmonary function by methods known to those skilled in the art.For example, various measurable parameters of pulmonary function can be tested before, during, or after treatment.Lung function can be monitored by testing any of several physically measurable lung functions, including but not limited to inhalation flow rate, exhalation flow rate, and lung volume.A statistically significant increase in one or more of these parameters, as determined by mathematical formulas and statistical methods, indicates the effectiveness of treatment.

[0128] The most commonly used method of measuring pulmonary function in clinical practice involves timed measurements of inhalation and exhalation to measure certain parameters. For example, FVC measures the total volume in liters that a patient forcefully exhales after first deep inhalation. By assessing this parameter in conjunction with FEV1, it is possible to quantitatively assess bronchoconstriction. A statistically significant increase in FVC or FEV1, as determined by formulas well known to those skilled in the art, reflects a decrease in bronchoconstriction, thereby indicating that treatment is effective.

[0129] The problem with determining forced vital capacity is that the performance related to forced vital capacity (i.e., the forced exhalation from maximum inspiration to maximum expiration) is highly technique-dependent. In other words, a given subject may produce different FVC values ​​during a series of consecutive FVC performances. FEF 25-75 or forced expiratory flow determined over the midpoint of the forced expiratory performance tends to be less technique-dependent than FVC. Similarly, FEV1 tends to be less technique-dependent than FVC. Thus, a statistically significant increase in FEF 25-75 or FEV1 determined by a formula known to those skilled in the art reflects a decrease in bronchoconstriction, thereby indicating that treatment is effective.

[0130] In addition to measuring the volume of exhaled air as an index of lung function, the flow rate in liters per minute measured over different parts of the expiratory cycle can be useful in determining the state of the lung function of a patient.Specifically, the peak expiratory flow rate obtained as the highest airflow rate in liters per minute during the forced maximum exhalation correlates well with the overall lung function of patients with asthma and other respiratory diseases.Therefore, a statistically significant increase in the peak expiratory flow rate determined by a formula known to those skilled in the art after administration indicates that the treatment is effective.

[0131] In some embodiments, subjects who have already been diagnosed with a cardiac disease or disorder, or a fibrosis-related disease, or graft rejection, and are in the process of treatment with another therapeutic agent to treat it, are selected for treatment. The therapeutic agent may be a chemical or biological agent, or may be a non-drug treatment such as diet and / or exercise. In some embodiments, the therapeutic agent (for cardiac disease or disorder) includes the use of a therapeutic agent that reduces the level of C-reactive protein (CRP). In other embodiments, the therapeutic agent (for cardiac disease or disorder) includes the use of a statin. In further embodiments, subjects with CRP levels above 1 mg / L are selected for treatment. The therapeutic agent may be, for example, an immunosuppressive agent when treating graft rejection. For example, treatment for fibrosis-related disease may be the use of an anti-inflammatory agent or an immunosuppressive agent.

[0132] In some embodiments, subjects who have had a primary (first) cardiovascular event, such as myocardial infarction, or have undergone angioplasty are selected for treatment with the disclosed method. Subjects who have had a primary cardiovascular event are at increased risk of a secondary (second) cardiovascular event. In some embodiments, subjects have not had a primary cardiovascular event, but are at increased risk of having a cardiovascular event due to the subject having one or more risk factors. Examples of risk factors for a primary cardiovascular event include hyperlipidemia, obesity, diabetes, hypertension, prehypertension, elevated level(s) of markers of systemic inflammation, age, family history of cardiovascular events, and smoking. The degree of risk of a cardiovascular event depends on the number and severity or magnitude of risk factors that a subject has. Risk charts and prediction algorithms are available to assess the risk of a cardiovascular event in a subject based on the presence and severity of risk factors. One such example is the Framingham Heart Study risk prediction score. If the subject's 10-year calculated Framingham Heart Study risk score is greater than or equal to 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, the subject is at increased risk of having a cardiovascular event. Another method for assessing the risk of a cardiovascular event in a subject is a global risk score that incorporates a measurement of the level of a marker of systemic inflammation, such as CRP, into the Framingham Heart Study risk prediction score. Other methods for assessing the risk of a cardiovascular event in a subject include coronary artery calcium scanning, cardiac magnetic resonance imaging, and / or magnetic resonance angiography. In some embodiments, the subject selected for treatment with the disclosed method has had a primary cardiovascular event and has one or more other risk factors. In another embodiment, the subject is undergoing treatment with a statin to reduce lipid levels. In another embodiment, the subject has healthy lipid levels (i.e., the subject is not hyperlipidemic).Thus, in one embodiment, MBV is administered to a patient according to the method of the present invention to prevent or reduce the risk of developing a cardiac disease or disorder in the patient. In other words, MBV is administered to a patient as a prophylaxis against a cardiac disease or disorder. In such an example, the patient is in need of prophylaxis due to exhibiting one or more risk factors for a cardiac disease or disorder, but the patient has not yet been diagnosed with a cardiac disease or disorder or has not exhibited all symptoms necessary for diagnosing a cardiac disease or disorder. In some embodiments, subjects who have or have had a stroke are selected for treatment. Stroke (also referred to herein as ischemic stroke and / or cerebrovascular ischemia) is defined by the World Health Organization as the rapid onset of clinical signs of focal or generalized cerebral dysfunction, with symptoms lasting for at least 24 hours. Stroke is also associated with death in the absence of obvious causes other than vascular effects. Stroke is generally caused by blockage or occlusion of blood vessels to or within the brain. Complete occlusion causes cessation of neuronal electrical activity within seconds due to cessation of cerebral circulation. Within minutes of deterioration of energy status and ion homeostasis, there is depletion of high-energy phosphates, membrane ion pump failure, efflux of intracellular potassium, influx of sodium chloride and water, and membrane depolarization. If occlusion persists for longer than 5-10 minutes, irreversible damage results. However, with incomplete ischemia, outcome is difficult to assess and depends largely on residual perfusion and oxygen availability. Ischemia is rarely complete after thrombotic occlusion of cerebral vessels. Depending on collateral circulation and local perfusion pressure, some residual perfusion usually persists in the ischemic area. The disclosed methods are useful in the treatment of stroke.

[0133] Although ischemic events can occur anywhere in the vasculature, the carotid bifurcation and the origin of the internal carotid artery are the most frequent sites of thrombotic occlusion of cerebral vessels resulting in cerebral ischemia. Symptoms of reduced blood flow due to stenosis or thrombosis are similar to those caused by middle cerebral artery disease. Blood flow through the ophthalmic artery is often affected enough to cause amaurosis fugax or transient monocular blindness. Severe bilateral internal carotid stenosis can result in hypoperfusion of the cerebral hemispheres. This manifests with acute headache ipsilateral to the acutely ischemic hemisphere. Occlusion or reduction in blood flow is accompanied by ischemia of one anterior cerebral artery distal to the anterior communicating artery, which results in motor and cortical sensory symptoms in the contralateral leg and, less frequently, the proximal arm. Other manifestations of anterior cerebral artery occlusion or inadequate perfusion include gait ataxia and sometimes urinary incontinence due to parasagittal frontal lobe damage. Speech impairment manifested as a decrease in spontaneous speech may be associated with a generalized decrease in psychomotor activity.

[0134] Subjects with stroke are diagnosed with stroke by the symptoms they experience and / or by physical examination, including interventional and non-interventional diagnostic tools such as CT and MR imaging.Subjects with stroke may show one or more of the following symptoms: paralysis, weakness, decreased sensation and / or vision, numbness, tingling, aphasia (e.g., inability to speak or slurred speech, difficulty in reading and writing), agnosia (i.e., inability to recognize or identify sensory stimuli), memory loss, difficulty in coordination, lethargy, drowsiness or loss of consciousness, lack of bladder or bowel control, and cognitive decline (e.g., dementia, limited attention span, inability to concentrate).Using medical imaging techniques, it may be possible to identify subjects with stroke as those with infarction or those with intracerebral hemorrhage.

[0135] The compositions and methods provided can be used for patients who have experienced stroke, and can be prophylactic treatment to prevent stroke. For subjects who have surgical or diagnostic procedures that are at risk of releasing emboli, lowering blood pressure, or reducing blood flow to the brain, short-term prophylactic treatment is indicated to reduce injury resulting from any ischemic events that occur as a result of the procedure. For subjects who have cardiac conditions that may lead to reduced blood flow to the brain, or conditions that directly affect the cerebral vasculature, long-term or chronic prophylactic treatment is indicated. If prophylactic, the treatment is for subjects at risk of ischemic stroke, as described above. If the subject has experienced stroke, the treatment can include acute treatment. Acute treatment for subjects with stroke means administering the composition of the present invention at or within 48 hours of the onset of symptoms of the condition, preferably within 24 hours, more preferably within 12 hours, more preferably within 6 hours, even more preferably within 1, 2 or 3 hours of the onset of symptoms of the condition, or immediately upon diagnosis, or when a stroke is suspected to have occurred by medical personnel.

[0136] In yet another embodiment, the subject may have myocardial infarction or may be at risk of having myocardial infarction. "Having myocardial infarction" means that the subject is currently having or has had myocardial infarction. In some embodiments, administration is performed before (when suspected or diagnosed in due course) or within 48 hours of cardiovascular event or diagnosis or suspicion of cardiac disease or disorder, but administration after cardiovascular event or diagnosis or suspicion of cardiac disease or disorder, for example within 14 days thereafter, may be beneficial for the subject. Immediate administration may also include administration within 15, 20, 30, 40 or 50 minutes, within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 20 or 22 hours, or within 1 or 2 days of cardiovascular event or diagnosis or suspicion of cardiac disease or disorder. In yet another embodiment, the MBV containing IL-33 can be administered for several days, a week, or several weeks (e.g., 1, 2, 3, or 4 weeks) beginning at or shortly after a cardiovascular event or diagnosis or suspicion of a cardiac disease or disorder.

[0137] Several clinical tests for diagnosing myocardial infarction are well known in the art.Generally, tests can be divided into four main categories: (1) non-specific indicators of tissue necrosis and inflammation, (2) electrocardiogram, (3) serum enzyme changes (e.g., creatine phosphokinase level), and (4) cardiac imaging.Those skilled in the art can easily apply any of the above tests to determine whether a subject is at risk of, suffers from, or has suffered from myocardial infarction.

[0138] The subject may have heart failure, a clinical syndrome of diverse etiology united by a common factor, impaired pumping function of the heart, characterized by the inability of the heart to pump blood in proportion to metabolic tissue demands or the ability to pump blood only through elevated filling pressures.

[0139] In yet another embodiment, the subject has cardiac hypertrophy. The condition is generally characterized by left ventricular hypertrophy, usually of nondilated chambers, without obvious antecedent cause. Current diagnostic methods include electrocardiogram and echocardiogram. However, many patients are asymptomatic and may be relatives of patients with known disease. Unfortunately, the first manifestation of the disease may be sudden death, which frequently occurs in children and young adults, often during or after exertion.

[0140] In another embodiment, the subject has an elevated level of a marker for heart disease or disorder or the risk thereof.The marker can be, for example, cholesterol, low-density lipoprotein cholesterol (LDLC) or a marker for systemic inflammation.The elevated level(s) of the marker is a level that exceeds the average of a healthy subject population (e.g., a human subject that does not have signs and symptoms of heart disease or disorder).When the marker is CRP, a CRP level>1 is considered as an elevated level.

[0141] Subjects with fibrosis can be selected. In some embodiments, the subject is diagnosed with liver cirrhosis, pulmonary fibrosis, cardiac fibrosis, mediastinal fibrosis, arthrofibrosis, bone marrow fibrosis, nephrogenic systemic fibrosis, keloid fibrosis, scleroderma fibrosis, renal fibrosis, lymphoid tissue fibrosis, arterial fibrosis, capillary fibrosis, vascular fibrosis, or pancreatic fibrosis. Subjects exposed to or at risk of exposure to inorganic particles, including but not limited to silica, asbestos, beryllium, coal dust, or bauxite, can be selected for treatment. Subjects with interstitial pulmonary fibrosis can be selected for treatment. Subjects with cardiac fibrosis can be selected for treatment. The disclosed methods can be used to treat or inhibit fibrosis in subjects.

[0142] The pharmaceutical composition may include MBV and, optionally, one or more additional agents. These compositions may be formulated in various ways to administer to a subject or to delay, prevent, reduce the risk of developing, or treat or reduce a disease process. The compositions described herein may also be formulated for applications in which the composition prevents metastasis of the initial lesion. In some embodiments, the composition is formulated for local administration, such as intracardiac administration. Local administration may be to a graft before and / or after implantation into a subject. MBV may be administered by any route, including parenteral administration, such as intravenous, intraperitoneal, intramuscular, intradermal, intraperitoneal, intrasternal, or intraarticular injection or infusion, or by sublingual, oral, topical, intranasal, or transmucosal administration, or by inhalation into the lungs. The appropriate route of administration may be selected by the physician. Pharmaceutical compositions including MBV may be formulated for both local and systemic use, and may be formulated for use in human or veterinary medicine. In some embodiments, the composition may be administered by injection or catheter. Administration can be intravenous or intramuscular.

[0143] The disclosed compositions can be administered once or repeatedly. The disclosed compositions can be administered locally or systemically. The disclosed compositions can be administered by intravenous injection, such as infusion, subcutaneous injection, topical administration or any other route, from once to several times a month, for example, twice a week, once a week, once every two weeks, or once every four weeks. Multiple treatments are envisioned, such as over a defined time interval, such as daily, twice a week, weekly, twice a month, or monthly. The administration schedule can be adjusted, for example, by extending the twice-weekly or weekly administration interval to once every two weeks, once every three weeks, or once every four weeks. In some embodiments, the method includes monitoring changes in organ function and / or blood test values ​​after transplantation. The composition can be administered to the subject before, at, or after organ transplantation. Administration can begin any time that disease inhibition or prevention is desired, for example, at a certain age of the subject or after receiving a solid organ transplant.

[0144] The disclosed methods and compositions are generally used to treat human subjects, but can also be used to treat similar or identical diseases in other vertebrates, such as other primates, dogs, cats, horses, and cattle. The appropriate administration format can best be determined for each subject individually by medical practitioners. Various pharmaceutically acceptable carriers and their formulations are described in standard formulation treatises, such as Remington's Pharmaceutical Sciences by EW Martin. See also Wang, YJ and Hanson, MA, Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42: 2S, 1988. The dosage form of the pharmaceutical composition is determined by the mode of administration selected. In some embodiments, the subject is a human and the MBV is derived from human tissue.

[0145] In some embodiments, the disclosed compositions increase muscle cell proliferation and / or reduce inflammation when administered locally to cells in an affected area or tissue of interest, such as a cardiac graft.

[0146] When MBVs (ECM-derived nanovesicles) are provided as parenteral compositions, for example for injection or infusion, they are generally suspended in an aqueous carrier, for example an isotonic buffer solution having a pH of about 3.0 to about 8.0, preferably about 3.5 to about 7.4, for example about 7.2 to about 7.4. Useful buffer solutions include sodium citrate-citric acid and sodium phosphate-phosphate, and sodium acetate-acetic acid buffers.

[0147] A form of sustained or "depot" slow release preparation can be used so that a therapeutically effective amount of the preparation is delivered into the bloodstream for a long time or days after injection or delivery. Suitable examples of sustained release compositions include suitable polymeric materials (e.g., semipermeable polymeric matrices in the form of shaped articles, e.g., films or microcapsules), suitable hydrophobic materials (e.g., emulsions in acceptable oils) or ion exchange resins, and sparingly soluble derivatives (e.g., sparingly soluble salts). Sustained release formulations can be administered orally, rectally, parenterally, intracisternally, vaginally, intraperitoneally, topically (as powders, ointments, gels, drops or transdermal patches), bucally, or as an oral or nasal spray. The pharmaceutical composition can be in the form of particles that include biodegradable polymers and / or polysaccharide jellification and / or bioadhesive polymers, amphiphilic polymers, agents that modify the interfacial properties of the particles, and pharmacologically active agents. These compositions exhibit certain biocompatible features that allow for the controlled release of active substances, see U.S. Patent No. 5,700,486.

[0148] The pharma- ceutically acceptable carriers and excipients useful in the disclosed method are conventional.For example, parenteral formulations usually contain injection fluids that are pharma- ceutical and physiologically acceptable fluid vehicles, such as water, physiological saline, other balanced salt solutions, aqueous dextrose, glycerol, etc. The excipients that can be included are, for example, proteins, such as human serum albumin or plasma preparations.If desired, the pharmaceutical composition to be administered can also contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents, for example, sodium acetate or sorbitan monolaurate.The actual preparation method of such dosage forms is known or will be clear to those skilled in the art.

[0149] The amount of MBV administered will depend on the subject being treated, the severity of the illness, and the mode of administration, and is best left to the judgment of the prescribing clinician. Within these constraints, the formulation administered will contain an amount of MBV in an amount effective to achieve the desired effect in the subject being treated.

[0150] The exact dosage can be easily determined by one skilled in the art based on the potency of the particular fraction, the age, weight, sex and physiological condition of the subject. Suitable concentrations include, but are not limited to, about 1 ng / ml to 100 gr / ml.

[0151] The method presented herein for treating a subject in need of treatment may include the use of additional therapeutic agents. The composition comprising MBV may also include additional therapeutic agents. Such additional therapeutic agents include antilipidemic agents, anti-inflammatory agents, antithrombotic agents, fibrinolytic agents, antiplatelet agents, direct thrombin inhibitors, glycoprotein IIb / IIIa receptor inhibitors, agents that bind to cell adhesion molecules and inhibit the ability of white blood cells to adhere to such molecules (e.g., anti-cell adhesion molecule antibodies), alpha-adrenergic blockers, beta-adrenergic blockers, cyclooxygenase-2 inhibitors, angiotensin system inhibitors, antiarrhythmic agents, calcium channel blockers, diuretics, inotropes, vasodilators, hypertensive agents, thiazolidinediones, cannabinoid-1 receptor blockers, immunosuppressants, and any combination thereof.

[0152] Antilipidemic agents are agents that reduce total cholesterol, reduce LDLC, reduce triglycerides, and / or increase HDLC. Antilipidemic agents include statins, nonstatin antilipidemic agents, and combinations thereof. Statins are a class of medicines that have been shown to be effective in lowering human total cholesterol, LDLC, and triglyceride levels. Statins act at the step of cholesterol synthesis. By reducing the amount of cholesterol synthesized by cells, statins initiate a cycle of events that culminates in increased uptake of LDLC by hepatocytes through inhibition of the HMG-CoA reductase gene. Increased uptake of LDLC reduces total cholesterol and LDLC levels in the blood. Low blood levels of both factors are associated with a lower risk of atherosclerosis and heart disease, and statins are widely used to reduce morbidity and mortality from atherosclerosis.

[0153] Examples of statins include, but are not limited to, simvastatin (ZOCOR®), lovastatin (MEVACOR®), pravastatin (PRAVACHOL®), fluvastatin (LESCOL®), atorvastatin (LIPITOR®), cerivastatin (BAYCOL®), rosuvastatin (CRESTOR®), pitavastatin, and the statins described in U.S. Pat. Nos. 4,444,784; 4,231,938; 4,311,621; and 4,421,235. 346,227;U.S. Patent No. 4,739,073;U.S. Patent No. 5,273,995;U.S. Patent No. 5,622,985;U.S. Patent No. 5,135,935;U.S. Patent No. 5,356,896;U.S. Patent No. 4,920,109;U.S. Patent No. 5,286,895;U.S. Patent No. 5,262,435;U.S. Patent No. 5,260,332;U.S. Patent No. 5,317,031;U.S. Patent No. 5,283,256;U.S. Patent No. 5,256,689;U.S. Patent No. 5,182,298;U.S. Patent No. 5,369,125;U.S. Patent No. 5,302,604 ;U.S. Patent No. 5,166,171;U.S. Patent No. 5,202,327;U.S. Patent No. 5,276,021;U.S. Patent No. 5,196,440;U.S. Patent No. 5,091,386;U.S. Patent No. 5,091,378;U.S. Patent No. 4,904,646;U.S. Patent No. 5,385,932;U.S. Patent No. 5,250,435;U.S. Patent No. 5,132,312;U.S. Patent No. 5,130,306;U.S. Patent No. 5,116,870;U.S. Patent No. 5,112,857,U.S. Patent No. 5,102,911;U.S. Patent No. 5,098,931;U.S. Patent No. 5, 081,136;U.S. Patent No. 5,025,000;U.S. Patent No. 5,021,453;U.S. Patent No. 5,017,716;U.S. Patent No. 5,001,144;U.S. Patent No. 5,001,128;U.S. Patent No. 4,997,837;U.S. Patent No. 4,996,234;U.S. Patent No. 4,994,494;U.S. Patent No. 4,992,429;U.S. Patent No. 4,970,231;U.S. Patent No. 4,968,693;U.S. Patent No. 4,963,538;U.S. Patent No. 4,957,940;U.S. Patent No. 4,950,675;U.S. Patent No. 4,946,864;Nos. 4,946,860; 4,940,800; 4,940,727; 4,939,143; 4,929,620; 4,923,861; 4,906,657; 4,906,624; and numerous others described in U.S. Patent No. 4,897,402.

[0154] Examples of statins that have already been approved for human use include atorvastatin, cerivastatin, fluvastatin, pravastatin, simvastatin and rosuvastatin.The following references provide further information on HMG-CoA reductase inhibitors: Drugs and Therapy Perspectives (May 12, 1997), 9: 1-6; Chong (1997) Pharmacotherapy 17: 1157-1177; Kellick (1997) Formulary 32: 352; Kathawala (1991) Medicinal Research Reviews, 11: 121-146; Jahng (1995) Drugs of the Future 20: 387-404, and Current Opinion in Lipidology, (1997), 8, 362-368. Another notable statin drug is Watanabe (1997) Bioorganic and Medicinal Chemistry 5: 437-444, compound 3a (S-4522).

[0155] Non-statin antihyperlipidemic agents include, but are not limited to, fibric acid derivatives (fibrates), bile acid sequestrants or resins, nicotinic acid agents, cholesterol absorption inhibitors, acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitors, cholesteryl ester transfer protein (CETP) inhibitors, LDL receptor antagonists, farnesoid X receptor (FXR) antagonists, sterol regulatory binding protein cleavage activating protein (SCAP) activators, microsomal triglyceride transfer protein (MTP) inhibitors, squalene synthase inhibitors and peroxisome proliferation-activated receptor (PPAR) agonists. Examples of fibric acid derivatives include, but are not limited to, gemfibrozil (LOPID®), fenofibrate (TRICOR®), clofibrate (ATROMID®) and bezafibrate. Examples of bile acid sequestrants or resins include, but are not limited to, colesevelam (WELCHOL®), cholestyramine (QUESTRAN® or PREVALITE®) and colestipol (COLESTID®), DMD-504, GT-102279, HBS-107 and S-8921. Examples of nicotinic acid agents include, but are not limited to, niacin and probucol. Examples of cholesterol absorption inhibitors include, but are not limited to, ezetimibe (ZETIA®).Examples of ACAT inhibitors include, but are not limited to, avasimibe, CI-976 (Parke Davis), CP-113818 (Pfizer), PD-138142-15 (Parke Davis), FF1394, as well as many others described in U.S. Pat. Nos. 6,204,278; 6,165,984; 6,127,403; 6,063,806; 6,040,339; 5,880,147; 5,621,010; 5,597,835; 5,576,335; 5,321,031; 5,238,935; 5,180,717; 5,149,709, and 5,124,337. Examples of CETP inhibitors include, but are not limited to, torcetrapib, CP-529414, CETi-1, JTT-705, and the following references: U.S. Pat. No. 6,727,277; U.S. Pat. No. 6,723,753; U.S. Pat. No. 6,723,752; U.S. Pat. No. 6,710,089; U.S. Pat. No. 6,699,898; U.S. Pat. No. 6,696,472; U.S. Pat. No. 6,696,435; U.S. Pat. No. 6,683,099; U.S. Pat. No. 6,677,382; U.S. Pat. No. 6,677,380; U.S. Pat. No. 6,677,379; U.S. Pat. No. 6,677,375; U.S. Pat. No. 6,677,353; U.S. Pat. No. 6,677,341; U.S. Pat. No. 6,605 No. 6,458,852; U.S. Patent No. 6,458,851; U.S. Patent No. 6,458,850; U.S. Patent No. 6,458,849; U.S. Patent No. 6,458,803; U.S. Patent No. 6,455,519; U.S. Patent No. 6,451,830; U.S. Patent No. 6,451,823; U.S. Patent No. 6,448,295; and numerous others described in U.S. Patent No. 5,512,548. One example of an FXR antagonist is guggulsterone.An example of SCAP activator is GW532 (GlaxoSmithKline).An example of MTP inhibitor includes but is not limited to implitapide and R-103757.An example of squalene synthase inhibitor includes but is not limited to zaragozic acid.An example of PPAR agonist includes but is not limited to GW-409544, GW-501516, and LY-510929.

[0156] Anti-inflammatory agents include, but are not limited to, alclofenac, alclometasone propionate, algestone acetonide, alpha amylase, amcinafal, amcinafide, amfenac sodium, amiprilose hydrochloride, anakinra, anilolac, anitrazafen, apazone, balsalazide disodium, bendazac, benoxaprofen, benzydamine hydrochloride, bromelain, broperamol, budesonide, carprofen, cycloprofen, synthazone, cliprofen, clobetasol propionate, and clobetasol. tazone butyrate, clopirac, cloticasone propionate, cormetasone acetate, cortodoxone, deflazacort, desonide, desoximetasone, dexamethasone propionate, diclofenac potassium, diclofenac sodium, diflorasone acetate, diflumidone sodium, diflunisal, difluprednate, diphthalone, dimethylsulfoxide, drocinonide, endrisone, enlimomab, enolicam sodium, epirizole, etodolac, etofenamate, felbinac, fenamol, fenbufen , Fenclofenac, Fenclorac, Fendosal, Fenpiparone, Fentiazac, Furazarone, Fluazacort, Flufenamic acid, Flumizole, Flunisolide acetate, Flunixin, Flunixin meglumine, Fluocortin butyl, Fluorometholone acetate, Fluquazone, Flurbiprofen, Fluretofen, Fluticasone propionate, Furaprofen, Flobufen, Halcinonide, Halobetasol propionate, Halopredone acetate, Ibufenac, Ibuprofen, Ibuprof aluminium, ibuprofen piconol, ilonidap, indomethacin, indomethacin sodium, indoprofen, indoxol, intrazol, isoflupredone acetate, isoxepac, isoxicam, ketoprofen, lofemizole hydrochloride, romoxicam, loteprednol etabonate, meclofenamate sodium, meclofenamic acid, meclorisone dibutyrate, mefenamic acid, mesalamine, meseclazone, methylprednisolone suleptanate, morniflumate, nabumetone, naproxen, naproxen sodium,Naproxol, Nimazone, Olsalazine Sodium, Orgotein, Orpanoxin, Oxaprozin, Oxyphenbutazone, Paranyline Hydrochloride, Pentosan Polysulfate Sodium, Phenbutazone Sodium Glycerate, Pirfenidone, Piroxicam, Piroxicam Cinnamate, Piroxicam Olamine, Pirprofen, Prednazate, Priferon, Prodolic Acid, Proquazone, Proxazole, Proxazole Citrate, Rimexolone, Romazarit, Sarcorex, Salnacedin, Salsalate, Salicylate, Sanguinarium Chloride Chloride), seclazone, selmetacin, sudoxicam, sulindac, suprofen, talmetacin, talniflumate, talosalate, tebufelone, tenidap, tenidap sodium, tenoxicam, tesicam, tesimide, tetridamine, tiopinac, tixocortol pivalate, tolmetin, tolmetin sodium, triclonide, triflumidate, zidometacin, glucocorticoids, and zomepirac sodium.

[0157] Antithrombotic and / or fibrinolytic agents include, but are not limited to, tissue plasminogen activators (e.g., ACTIVASE®, ALTEPLASE®), which catalyze the conversion of inactive plasminogen to plasmin. This may occur through the interaction of prekallikrein, kininogen, factor XII, factor XIIIa, plasminogen proactivator, and tissue plasminogen activator (TPA), streptokinase, urokinase, anisoylated plasminogen-streptokinase activator complex, pro-urokinase, (pro-UK), rTPA (ACTIVASE®, ALTEPLASE®); r indicates recombinant), rpro-UK, abokinase, eminase, septase, anagrelide hydrochloride, bivalirudin, dalteparin sodium, danaparoid sodium, dazoxiben hydrochloride, efegatran sulfate, enoxaparin sodium, ifetroban, ifetroban sodium, tinzaparin sodium, retaplase, trifenagrel, warfarin, dextran, aminocaproic acid (AMICAR®), and tranexamic acid (AMSTAT®).

[0158] Antiplatelet agents include, but are not limited to, Clopridogrel, Sulfinpyrazone, Aspirin, Dipyridamole, Clofibrate, Pyridinol Carbamate, PGE, Glucagon, Antiserotonin Drugs, Caffeine, Theophylline Pentoxifylline, Ticlopidine, and Anagrelide. Direct thrombin inhibitors include, but are not limited to, Hirudin, Hirugen, Hirulog, Argatroban, PPACK, and Thrombin Aptamers. Glycoprotein IIb / IIIa receptor inhibitors include both antibodies and non-antibodies, including, but are not limited to, REOPRO® (abcixamab), lamifiban, and tirofiban. Agents that bind to cell adhesion molecules and inhibit the ability of white blood cells to adhere to such molecules include polypeptide agents. Such polypeptides include polyclonal and monoclonal antibodies prepared according to conventional methodologies. Such antibodies are already known in the art and include anti-ICAM1 antibodies and other such antibodies.

[0159] Examples of alpha-adrenergic blockers include, but are not limited to, doxazocin, prazocin, tamsulosin, and tarazosin. Beta-adrenergic receptor blockers are a class of drugs that antagonize the cardiovascular effects of catecholamines in angina, hypertension, and cardiac arrhythmias. Beta-adrenergic receptor blockers include, but are not limited to, atenolol, acebutolol, alprenolol, befunolol, betaxolol, bunitrolol, carteolol, celiprolol, hydroxalol, indenolol, labetalol, levobunolol, mepindolol, metipranol, methindol, metoprolol, metrizolanol, oxprenolol, pindolol, propranolol, practolol, practolol, sotalornadolol, tiprenolol, tomalolol, timolol, bupranolol, penbutolol, trimepranolol, 2- (3-(1,1-dimethylethyl)-amino-2-hydroxypropoxy)-3-pyridenecarbonitrile HCl, 1-butylamino-3-(2,5-dichlorophenoxy)-2-propanol, 1-isopropylamino-3-(4-(2-cyclopropylmethoxyethyl)phenoxy)-2-propanol, 3-isopropylamino-1-(7-methylindan-4-yloxy)-2-butanol, 2-(3-t-butylamino-2-hydroxy-propylthio)-4-(5-carbamoyl-2-thienyl)thiazole, 7-(2-hydroxy-3-t-butylaminopropoxy)phthalide. The above identified compounds may be used as isomeric mixtures or in their respective left-handed or right-handed forms.

[0160] Selective COX-2 inhibitors are known in the art and are available. These include, but are not limited to, the F COX-2 inhibitors described in U.S. Pat. Nos. 5,521,213; 5,536,752; 5,550,142; 5,552,422; 5,604,253; 5,604,260; 5,639,780; 5,677,318; 5,691,374; 5,698,584; 5,710,140; 5,733,909; 5,789,413; 5,817,700; 5,849,943; 5,861,419; 5,922,742; 5,925,631; and 5,643,933. Some of the above-identified COX-2 inhibitors are prodrugs of selective COX-2 inhibitors and exert their action by being converted in vivo to active and selective COX-2 inhibitors. Active and selective COX-2 inhibitors formed from the above-identified COX-2 inhibitor prodrugs are described in PCT Publication No. WO 95 / 00501, PCT Publication No. WO 95 / 18799, and U.S. Patent No. 5,474,995.

[0161] Angiotensin system inhibitors are drugs that interfere with the function, synthesis or catabolism of angiotensin II. These drugs include, but are not limited to, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II antagonists, angiotensin II receptor antagonists, drugs that activate the catabolism of angiotensin II, and drugs that interfere with the synthesis of angiotensin I, which ultimately results in angiotensin II. Examples of such classes of compounds include antibodies (e.g., against renin), amino acids and their analogs (including those conjugated with larger molecules), peptides (including peptide analogs of angiotensin and angiotensin I), pro-renin related analogs, and the like. The most potent and useful renin-angiotensin system inhibitors include renin inhibitors, ACE inhibitors, and angiotensin II antagonists.

[0162] Angiotensin II antagonists are compounds that interfere with the activity of angiotensin II by binding to and interfering with the activity of the angiotensin II receptor. Angiotensin II antagonists are well known and include peptide and non-peptide compounds. Most angiotensin II antagonists are slightly modified congeners in which the phenylalanine at position 8 is replaced with some other amino acid to attenuate agonist activity. Stability can be enhanced by other substitutions that slow degradation in vivo. Examples of angiotensin II receptor antagonists include, but are not limited to, candesartan (Alacand), IRBESARTAN® (Avapro), losartan (COZAARS®), telmisartan (MICARDIS®), and valsartan (DIOVAN®). Other examples of angiotensin II antagonists include peptide compounds (e.g., saralasin, [(Sar 1 )(Val 5 )(Ala 8)]angiotensin-(1-8) octapeptide and related analogues; N-substituted imidazol-2-ones (U.S. Pat. No. 5,087,634); imidazole acetic acid derivatives including 2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid (Long et al., J. Pharmacol. Exp. Ther. 247 (1), 1-7 (1988); 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid and analogous derivatives (U.S. Pat. No. 4,816,463); N2-tetrazole beta-glucuronide analogs (U.S. Pat. No. 5,085,992); substituted pyrroles, pyrazoles, and triazoles (U.S. Pat. No. 5,081,127); phenols and heterocyclic derivatives, such as 1,3-imidazoles (U.S. Pat. No. 5,073,566); imidazo-fused 7-membered heterocycles (U.S. Pat. No. 5,064,82 No. 5); peptides (e.g., U.S. Pat. No. 4,772,684); antibodies against angiotensin II (e.g., U.S. Pat. No. 4,302,386); and aralkylimidazole compounds such as biphenyl-methyl substituted imidazoles (e.g., EP No. 253,310, Jan. 20, 1988); ES8891 (N-morpholinoacetyl-(-1-naphthyl)-L-alanyl-(4,thiazolyl)-L-alanyl(35,45)-4-amino-3-hydroxy-5-cyclohexapentanoyl-N-hexylamide, Sankyo Company, Ltd., Tokyo, Japan); SKF108566 (E-alpha-2-[2-butyl-1-(carboxyphenyl)methyl]1H-imidazol-5-yl[methylan]-2-thiophenepropanoic acid, Smith Kline Beecham Pharmaceuticals, PA); LOSARTAN® (DUP753 / MK954, DuPont Merck Pharmaceutical Company); Remikirin (RO42-5892, F. Hoffman LaRoche AG); A2 agonists (Marion Merrill Dow) as well as certain non-peptide heterocycles (GD Searle and Company).

[0163] Angiotensin-converting enzyme (ACE) is an enzyme that catalyzes the conversion of angiotensin I to angiotensin II. ACE inhibitors include amino acids and their derivatives, peptides, including dipeptides and tripeptides, and antibodies against ACE that inhibit the activity of ACE, thereby interfering with the renin-angiotensin system by reducing or eliminating the formation of the hypertensive substance angiotensin II. ACE inhibitors are used medically to treat hypertension, congestive heart failure, myocardial infarction, and renal disease. Classes of compounds known to be useful as ACE inhibitors include acyl mercapto and mercaptoalkanoyl prolines, such as captopril (U.S. Pat. No. 4,105,776) and zofenopril (U.S. Pat. No. 4,316,906); enalapril (U.S. Pat. No. 4,374,829); lisinopril (U.S. Pat. No. 4,374,829); quinapril (U.S. Pat. No. 4,344,949); ramipril (U.S. Pat. No. 4,587,258); No. 4,508,729), and carboxyalkyl dipeptides such as perindopril (U.S. Pat. No. 4,508,729); carboxyalkyl dipeptide mimetics such as cilazapril (U.S. Pat. No. 4,512,924) and benazapril (U.S. Pat. No. 4,410,520); and phosphinylalkanoyl prolines such as fosinopril (U.S. Pat. No. 4,337,201) and trandolopril.

[0164] Renin inhibitors are compounds that interfere with the activity of renin. Renin inhibitors include amino acids and their derivatives, peptides and their derivatives, and antibodies against renin. Examples of renin inhibitors that are the subject of U.S. patents are: urea derivatives of peptides (U.S. Pat. No. 5,116,835); non-peptide linked amino acids (U.S. Pat. No. 5,114,937); dipeptide and tripeptide derivatives (U.S. Pat. No. 5,106,835); amino acids and their derivatives (U.S. Pat. Nos. 5,104,869 and 5,095,119); diol sulfonamides and sulfinyls (U.S. Pat. No. 5,098,924); modified peptides (U.S. Pat. No. 5,095,006); peptidyl beta-aminoacyl aminodiol carbamates (U.S. Pat. No. 5,089,471); pyrrole imidazolones (U.S. Pat. No. 5,075,451); fluorine and chlorine statins or peptidyl aminodiols (U.S. Patents. 5,063,208 and 4,845,079); N-morpholino derivatives (U.S. Patent 5,055,466); pepstatin derivatives (U.S. Patent 4,980,283); N-heterocyclic alcohols (U.S. Patent 4,885,292); monoclonal antibodies against renin (U.S. Patent 4,780,401); and various other peptides and analogs thereof (U.S. Patent 5,071,837; U.S. Patent 5,064,965; U.S. Patent 5,063,207; U.S. Patent 5,036,054; U.S. Patent 5,036,053, U.S. Patent 5,034,512, and U.S. Patent 4,894,437).

[0165] Calcium channel blockers are a chemically diverse class of compounds that have important therapeutic value in the control of a variety of diseases, including several cardiovascular disorders such as hypertension, angina pectoris, and cardiac arrhythmias (Fleckenstein, Cir. Res. v. 52, (suppl. 1), p. 13-16 (1983);Fleckenstein, Experimental Facts and Therapeutic Prospects, John Wiley, New York (1983);McCall, D., Curr Pract Cardiol, v. 10, p. 1-11 (1985)). Calcium channel blockers are a heterogeneous group of drugs that prevent or slow the entry of calcium into cells by modulating cellular calcium channels. (Remington, The Science and Practice of Pharmacy, Nineteenth Edition, Mack Publishing Company, Eaton, Pa., p. 963 (1995)). Most of the calcium channel blockers currently available and useful according to the present invention belong to one of three major chemical classes of drugs: dihydropyridines, e.g., nifedipine, phenylalkylamines, e.g., verapamil, and benzothiazepines, e.g., diltiazem. Other calcium channel blockers useful according to the present invention include, but are not limited to, aminone, amlodipine, bencyclane, felodipine, fendiline, flunarizine, isradipine, nicardipine, nimodipine, perhexylene, gallopamil, tiapamil and tiapamil analogs (such as, for example, 1993RO-11-2933), phenyloin, barbiturates, and the peptide dynorphins, omega-conotoxins, and omega-agatoxins, and the like, and / or pharma-ceutically acceptable salts thereof.

[0166] Diuretics include, but are not limited to, carbonic anhydrase inhibitors, loop diuretics, potassium-sparing diuretics, thiazides and related diuretics. Vasodilators include, but are not limited to, coronary vasodilators and peripheral vasodilators. Vasopressors are agents that cause vasoconstriction and / or increase blood pressure. Vasopressors include, but are not limited to, dopamine, ephedrine, epinephrine, methoxamine HCl (VASOXYL®), phenylephrine, phenylephrine HCl (NEO-SYNEPHRINE®), and metaraminol. Thiazolidinediones include, but are not limited to, rosigletazone (AVANDIA®), pioglitazone (ACTOS®), troglitazone (Rezulin), any of which may be used in the disclosed methods and compositions.

[0167] Immunosuppressants include, but are not limited to, steroids, calcineurin inhibitors, anti-proliferative agents, biologics, and monoclonal or polyclonal antibodies. Biologics include, but are not limited to, recombinant or synthetic peptides and proteins, and synthetic forms of nucleic acids. The steroids may be corticosteroids. Examples of corticosteroids include, but are not limited to, prednisone, hydrocortisone, and methylprednisone. Examples of calcineurin inhibitors include, but are not limited to, tacrolimus, FK506, ADVAGRAFT®, PROGRAF®, ENVARSUS XR®, HECORIA®, ASTAGRAF XL®, and cyclosporine (CEQUAS®, NEORAL®, RESTASIS®), NEORAL®, PIMECROLIMUS®, SANDIMMUNE®, PROTOPIC®, GENGRAFT®, and ELIDEL®.Examples of monoclonal antibodies include, but are not limited to, anti-CD3 antibodies (muromonab-CD3, ORTHOCLONE® OKT3), visilizumab (NUVION®), anti-CD52 (alemtuzumab (CAMPATH®-1H)), anti-CD25 (basiliximab (SIMULECT®)), anti-CD20 (rituximab (RITUXAN®), obinutuzumab (GAZYVA®), ocrelizumab (OCREVUS®)), anti-complement proteins (eculizumab (SOLIRIS®)), anti-costimulatory molecules (anti-CD3 antibodies), anti-CD40 antibodies (anti-CD40 antibodies), anti-CD52 antibodies (alemtuzumab (CAMPATH®-1H)), anti-CD25 antibodies (basiliximab (SIMULECT®)), anti-CD20 antibodies (rituximab (RITUXAN®), obinutuzumab (GAZYVA®), ocrelizumab (OCREVUS®)), anti-complement proteins (eculizumab (SOLIRIS®)), anti-costimulatory molecules (anti-CD40 antibodies), anti-CD40 antibodies ... anti-cytokine or cytokine receptor (tocilizumab (ACTEMRA®), ustekinumab (STELARA®), canakinumab (ILARIS®), secukinumab (COSENTYX®), siltuximab (SYLVANT®), brodalumab (SILIQ®), ixekizumab (TALTZ®), sarilumab (KEVAZRA®), guselkumab (TREMFYA®), and tildrakizumab (ILUMYA®)). Examples of polyclonal antibodies include, but are not limited to, anti-thymocyte globulin-equine (ATGAM®) and anti-thymocyte globulin-rabbit (RATG thymoglobulin), polyclonal human IgG immunoglobulin (IVIG, BIVIGAM®, CARIMUNE®, CUTAQUIG®). Examples of biological proteins include, but are not limited to, soluble CTLA-4-Ig (ABATACEPT®), C1-esterase inhibitors (C1-INH, CINRYZE®, HAEGARDA®), IL-1 or IL-1R antagonists (anakinra (KINERET®), rilonacept (ARCALYST®), and Streptococcus pyogenes IgG-degrading enzyme (IdeS).Antiproliferative or antimetabolite agents include, but are not limited to, mycophenolate mofetil, mycophenolate sodium, azathioprine, cyclophosphamide, rapamycin, sirolimus (RAPAMUNE®), everolimus (AFINITOR®). Other immunosuppressants include, but are not limited to, sulfasalazine, azulfidine, methoxsalen, and thalidomide, any of which may be used in the disclosed compositions and methods. In some embodiments, the immunosuppressant is a calcineurin inhibitor, an antiproliferative agent, an mTOR inhibitor, and / or a steroid. In certain non-limiting examples, the calcineurin inhibitor is tacrolimus or cyclosporine, the antiproliferative agent is mycophenolic acid, the mTOR inhibitor is sirolimus, and / or the steroid is prednisone, hydrocortisone, or cortisone.

[0168] The presented method may also include the use of other treatments, such as diet and / or exercise. In some embodiments, these treatments are added to the therapeutic treatment with MBV. "Co-administering" as used herein refers to administering two or more therapeutic agents (e.g., MBV and a second therapeutic agent) simultaneously as a mixture in a single composition, or sequentially, and in some embodiments, close enough in time that the compounds can exert additive or even synergistic effects. In other embodiments, the therapeutic agents are administered in combination. In still other embodiments, one therapeutic agent is administered before or after another therapeutic agent.

[0169] The dose of MBV administered is therapeutically effective and depends on several factors, including the route of administration, and can be determined by a skilled clinician. In some embodiments, the concentration of MBV is about 1×10 per ml. 5 ~Approx. 1×10 12 pcs, e.g. 1 x 10 per ml 6 ~Approx. 1×10 11 Approximately 1 x 10 per ml7 ~Approx. 1×10 11 or approximately 1 x 10 per ml 8 ~Approx. 1×10 10 In some non-limiting examples, when administered topically, the concentration is about 1×10 per ml. 8 ~Approx. 1×10 10 A dose of about 1 x 10 per ml, for example 8 Approximately 5 x 10 per ml 8 Approximately 1 x 10 per ml 9 Approximately 5 x 10 per ml 9 or approximately 1 x 10 per ml 10 When administered locally, the volume is appropriate for the site. Exemplary, non-limiting volumes are 0.1 ml intravitreal, 1.0 ml when diffused over the surface of the implantation area, 1.5 ml when injected into the margin of a 3 cm long skin incision, and approximately 1.40 mm2 of the entire cavity. 3 For injection into the stroke cavity, the volume is 0.15 ml. One of skill in the art can easily identify an appropriate volume for the location. In general, the volume is effective for treatment and does not induce damage at the desired site.

[0170] In general, the dose of the active compound or agent may be from about 0.01 mg / kg per day to 1000 mg / kg per day. It is expected that doses ranging from 1-5 mg / kg, 5-50 mg / kg or 50-100 mg / kg may be suitable for oral administration in one or several doses per day. Other forms of administration, such as intravenous administration, provide lower doses. If the response in human subjects is inadequate with the initial dose applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be used, as long as patient tolerance allows. Multiple doses per day are contemplated to achieve adequate systemic levels of the compound.

[0171] When administered, pharmaceutical preparations are applied as pharma- ceutically acceptable compositions in pharma- ceutically acceptable amounts. Such preparations routinely contain salts, buffers, preservatives, compatible carriers, and other therapeutic agents as necessary. When used in medicine, salts should be pharma- ceutically acceptable, but salts that are not pharma- ceutically acceptable can also be conveniently used to prepare pharma- ceutically acceptable salts and are not excluded from the scope of the present invention. Such pharmacologically and pharma- ceutically acceptable salts include, but are not limited to, salts prepared from the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, maleic acid, acetic acid, salicylic acid, citric acid, formic acid, malonic acid, succinic acid, and the like. Pharmaceutically acceptable salts can also be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium, or calcium salts. See U.S. Published Application No. 2008 / 0003199, IL-33 in the treatment and diagnosis of diseases and disorders, which is incorporated herein by reference. Methods for increasing myoblast differentiation - Patents.com

[0172] Also disclosed are methods for increasing myoblast differentiation, comprising contacting myoblasts with an effective amount of isolated extracellular matrix derived nanovesicles, the nanovesicles containing interleukin (IL)-33 and containing lysyl oxidase, the nanovesicles a) expressing neither CD63 nor CD81, or b) expressing CD63. lo CD81 lo The myoblasts may be in vivo or in vitro.

[0173] Myogenesis, the process of muscle cell specification, differentiation, and fusion into multinucleated syncytia, is essential for normal muscle development and tissue regeneration after injury.

[0174] In some embodiments, treatments aimed at limiting the consequences of post-infarction cardiac dysfunction include transplanting cells (muscle cells or stem cells) into the damaged left ventricle. The transplanted cells increase the ventricular ejection fraction by participating in cardiac contraction. A large number of potentially contractile cells is required for intramyocardial transplantation. Thus, the disclosed method can expand a cell population suitable for use as a cardiac or skeletal muscle graft. Exemplary embodiments

[0175] Clause 1. A method for treating or inhibiting a disorder in a subject having or at risk of having the disorder, comprising the steps of selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated extracellular matrix derived nanovesicles, wherein the nanovesicles contain interleukin (IL)-33 and contain lysyl oxidase, and the nanovesicles a) do not express CD63 or CD81, or b) express CD63 or CD81. lo CD81 lo and, whereby a disorder in a subject is treated or inhibited, wherein the disorder is a) organ or tissue fibrosis; b) parenchymal organ transplant rejection; or c) a cardiac disease that is not myocardial infarction or myocardial ischemia.

[0176] Clause 2. The method of clause 1, wherein the extracellular matrix is ​​a mammalian extracellular matrix.

[0177] Clause 3. The method of clause 2, wherein the mammalian extracellular matrix is ​​a human extracellular matrix.

[0178] Clause 4. The method of any one of clauses 1 to 3, wherein the extracellular matrix is ​​derived from esophageal tissue, urinary bladder, small intestinal submucosa, dermis, umbilical cord, pericardium, cardiac tissue, or skeletal muscle.

[0179] Clause 5. The method of any one of clauses 1 to 4, wherein the nanovesicles comprise miR-145 and / or miR-181.

[0180] Clause 6. The method of any one of clauses 1 to 5, wherein the disorder is solid organ graft rejection and the subject is a recipient of a transplanted solid organ.

[0181] Clause 7. The method of clause 6, wherein the nanovesicles are administered to a transplanted solid organ.

[0182] Clause 8. The method according to clause 7, wherein the transplanted solid organ is the heart.

[0183] Clause 9. The method according to any one of clauses 1 to 5, wherein the disorder is a cardiac disease.

[0184] Clause 10. The method of any one of clauses 1 to 5, wherein the cardiac disease is heart failure or cardiac ischemia.

[0185] Clause 11. The method of any of clauses 1 to 5, wherein the cardiac disease comprises acute coronary syndrome, chronic stable angina, unstable angina, angioplasty, transient ischemic attack, ischemic reperfusion injury, claudication, vascular occlusion, arteriosclerosis, heart failure, chronic heart failure, acute decompensated heart failure, cardiac hypertrophy, cardiac fibrosis, aortic valve disease, aortic or mitral stenosis, cardiomyopathy, atrial fibrillation, cardiac arrhythmia, and pericardial disease.

[0186] Clause 12. The method of any one of clauses 1 to 11, wherein the nanovesicles are administered intravenously.

[0187] Clause 13. The method of any one of clauses 1 to 5, wherein the disorder is organ or tissue fibrosis.

[0188] Clause 14. The method according to clause 13, wherein the fibrosis is liver cirrhosis, pulmonary fibrosis, cardiac fibrosis, mediastinal fibrosis, arthrofibrosis, bone marrow fibrosis, nephrogenic systemic fibrosis, keloid fibrosis, scleroderma fibrosis, renal fibrosis, lymphoid tissue fibrosis, arterial fibrosis, capillary fibrosis, vascular fibrosis, or pancreatic fibrosis.

[0189] Clause 15. The method according to clause 14, wherein the fibrosis is pulmonary fibrosis.

[0190] Clause 16. The method according to clause 14, wherein the fibrosis is cardiac fibrosis.

[0191] Article 17. Cardiac fibrosis a) hypertrophic cardiomyopathy, sarcoidosis, chronic renal failure, toxic cardiomyopathy, ischemia-reperfusion injury, acute organ rejection, chronic organ rejection, aging, chronic hypertension, non-ischemic delated cardiomyopathy, arrhythmias, atherosclerosis, HIV-associated chronic vascular disease, and pulmonary hypertension; or b) Myocardial infarction or myocardial ischemia The method according to clause 16,

[0192] Clause 18. The method of clause 15, wherein the nanovesicles are administered to the patient by inhalation.

[0193] Clause 19. The method of any one of clauses 1 to 16, wherein the nanovesicles are administered to the subject weekly, twice monthly, or monthly.

[0194] Clause 20. The method of any one of clauses 1 to 19, further comprising administering to the subject a therapeutically effective amount of an additional therapeutic agent.

[0195] Clause 21. The method of clause 20, wherein the additional therapeutic agent is an immunosuppressant.

[0196] Clause 22. The method of clause 21, wherein the immunosuppressant is a calcineurin inhibitor, an antiproliferative agent, an mTOR inhibitor, and / or a steroid.

[0197] Clause 23. The method of clause 22, wherein the calcineurin inhibitor is tacrolimus or cyclosporine, the antiproliferative agent is mycophenolic acid, the mTOR inhibitor is sirolimus, and / or the steroid is prednisone, hydrocortisone, or cortisone.

[0198] Clause 24. The method of any one of clauses 1 to 23, wherein the subject is a human.

[0199] Clause 25. A method for treating or inhibiting a disorder in a subject having or at risk of having the disorder, comprising the steps of selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated extracellular matrix derived nanovesicles, wherein the nanovesicles contain interleukin (IL)-33 and contain lysyl oxidase, and the nanovesicles a) do not express CD63 or CD81, or b) express CD63 or CD81. lo CD81 lo and b. administering to the subject a therapeutically effective amount of at least one of the following:

[0200] Clause 26. The method of clause 25, wherein the extracellular matrix is ​​a mammalian extracellular matrix.

[0201] Clause 27. The method of clause 26, wherein the mammalian extracellular matrix is ​​a human extracellular matrix.

[0202] Clause 28. The method of any one of clauses 25 to 27, wherein the extracellular matrix is ​​derived from esophageal tissue, urinary bladder, small intestinal submucosa, dermis, umbilical cord, pericardium, cardiac tissue, or skeletal muscle.

[0203] Clause 29. The method of any one of clauses 25 to 28, wherein the nanovesicles comprise miR-145 and / or miR-181.

[0204] Clause 30. The method of any one of clauses 25 to 29, wherein the fibrosis is liver cirrhosis, pulmonary fibrosis, cardiac fibrosis, mediastinal fibrosis, arthrofibrosis, bone marrow fibrosis, nephrogenic systemic fibrosis, keloid fibrosis, scleroderma fibrosis, renal fibrosis, lymphoid tissue fibrosis, arterial fibrosis, capillary fibrosis, vascular fibrosis, or pancreatic fibrosis.

[0205] Clause 31. The method according to clause 30, wherein the fibrosis is pulmonary fibrosis.

[0206] Clause 32. The method of clause 30, wherein the fibrosis is cardiac fibrosis.

[0207] Article 33. Cardiac fibrosis a) hypertrophic cardiomyopathy, sarcoidosis, chronic renal failure, toxic cardiomyopathy, ischemia-reperfusion injury, acute organ rejection, chronic organ rejection, aging, chronic hypertension, nonischemic dilated cardiomyopathy, arrhythmias, atherosclerosis, HIV-associated chronic vascular disease, and pulmonary hypertension; or b) Myocardial infarction or myocardial ischemia The method according to clause 32,

[0208] Clause 33.1. The method of clause 33, wherein the cardiac fibrosis is caused by acute organ rejection.

[0209] Clause 33.2. The method of clause 33, wherein the cardiac fibrosis is caused by chronic organ rejection.

[0210] Clause 34. The method according to any one of clauses 25 to 33.2, wherein the nanovesicles are administered to the patient by inhalation or intravenously.

[0211] Clause 35. The method of any one of clauses 25 to 33.2, wherein the nanovesicles are administered to the subject weekly, twice monthly, or monthly.

[0212] Clause 36. The method of any one of clauses 25 to 35, further comprising administering to the subject a therapeutically effective amount of an additional therapeutic agent.

[0213] Clause 37. The method of clause 36, wherein the additional therapeutic agent is an immunosuppressant.

[0214] Clause 38. The method of clause 37, wherein the immunosuppressant is a calcineurin inhibitor, an antiproliferative agent, an mTOR inhibitor, and / or a steroid.

[0215] Clause 39. The method of clause 38, wherein the calcineurin inhibitor is tacrolimus or cyclosporine, the antiproliferative agent is mycophenolic acid, the mTOR inhibitor is sirolimus, and / or the steroid is prednisone, hydrocortisone, or cortisone.

[0216] Clause 40. The method of any one of clauses 25 to 39, wherein the subject is a human.

[0217] Clause 41. A method for treating or inhibiting a disorder in a subject having or at risk of having the disorder, comprising the steps of selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated extracellular matrix derived nanovesicles, the nanovesicles containing interleukin (IL)-33 and containing lysyl oxidase, the nanovesicles a) expressing neither CD63 nor CD81, or b) expressing CD63 lo CD81 lo and b. administering to the subject a therapeutically effective amount of a therapeutically effective amount of a medicament for treating or inhibiting a disorder in a subject, the disorder being solid organ transplant rejection.

[0218] Clause 42. The method of clause 41, wherein the extracellular matrix is ​​a mammalian extracellular matrix.

[0219] Clause 43. The method of clause 42, wherein the mammalian extracellular matrix is ​​a human extracellular matrix.

[0220] Clause 44. The method of any one of clauses 41 to 43, wherein the extracellular matrix is ​​derived from esophageal tissue, urinary bladder, small intestinal submucosa, dermis, umbilical cord, pericardium, cardiac tissue, or skeletal muscle.

[0221] Clause 45. The method of any one of clauses 41 to 43, wherein the nanovesicles comprise miR-145 and / or miR-181.

[0222] Clause 46. The method of any one of clauses 41 to 45, wherein the nanovesicles are administered to a transplanted solid organ.

[0223] Clause 47. The method according to clause 46, wherein the transplanted solid organ is the heart.

[0224] Clause 47.1. The method according to clause 46, wherein the transplanted solid organ is a lung, a kidney or a liver.

[0225] Clause 48. The method of any one of clauses 41 to 47.1, wherein the nanovesicles are administered intravenously.

[0226] Clause 49: The method of any one of clauses 41 to 46 and 47.1, wherein the nanovesicles are administered by inhalation.

[0227] Clause 50. The method of any one of clauses 41 to 49, wherein the nanovesicles are administered to the subject weekly, twice monthly, or monthly.

[0228] Clause 51. The method of any one of clauses 41 to 50, further comprising administering to the subject a therapeutically effective amount of an additional therapeutic agent.

[0229] Clause 52. The method of clause 51, wherein the additional therapeutic agent is an immunosuppressant.

[0230] Clause 53. The method of clause 52, wherein the immunosuppressant is a calcineurin inhibitor, an antiproliferative agent, an mTOR inhibitor, and / or a steroid.

[0231] Clause 54. The method of clause 53, wherein the calcineurin inhibitor is tacrolimus or cyclosporine, the antiproliferative agent is mycophenolic acid, the mTOR inhibitor is sirolimus, and / or the steroid is prednisone, hydrocortisone, or cortisone.

[0232] Clause 55. The method of any one of clauses 41 to 54, wherein the subject is a human.

[0233] Clause 55.1. The method according to any one of clauses 41 to 55, wherein the solid organ graft rejection is acute rejection.

[0234] Clause 55.2. The method of any one of clauses 41 to 55, wherein the solid organ graft rejection is a chronic rejection.

[0235] Clause 56. A method for treating or inhibiting a disorder in a subject having or at risk of having the disorder, comprising the steps of selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated extracellular matrix derived nanovesicles, wherein the nanovesicles contain interleukin (IL)-33 and contain lysyl oxidase, and the nanovesicles a) do not express CD63 or CD81, or b) express CD63 or CD81. lo CD81 lo and b. administering to the subject a therapeutically effective amount of a therapeutically effective amount of a medicament for treating or inhibiting a disorder in the subject, wherein the disorder is a cardiac disease that is not a myocardial infarction or myocardial ischemia.

[0236] Clause 57. The method of clause 56, wherein the extracellular matrix is ​​a mammalian extracellular matrix.

[0237] Clause 58. The method of clause 57, wherein the mammalian extracellular matrix is ​​a human extracellular matrix.

[0238] Clause 59. The method of any one of clauses 56 to 58, wherein the extracellular matrix is ​​derived from esophageal tissue, urinary bladder, small intestinal submucosa, dermis, umbilical cord, pericardium, cardiac tissue, or skeletal muscle.

[0239] Clause 60. The method of any one of clauses 55 to 58, wherein the nanovesicles comprise miR-145 and / or miR-181.

[0240] Clause 61. The method of any one of clauses 56 to 60, wherein the cardiac disease is cardiac failure or cardiac ischemia.

[0241] Clause 62. The method of any of clauses 56 to 60, wherein the cardiac disease comprises acute coronary syndrome, chronic stable angina, unstable angina, angioplasty, transient ischemic attack, ischemic reperfusion injury, claudication, vascular occlusion, arteriosclerosis, heart failure, chronic heart failure, acute decompensated heart failure, cardiac hypertrophy, cardiac fibrosis, aortic valve disease, aortic or mitral stenosis, cardiomyopathy, atrial fibrillation, cardiac arrhythmia, and pericardial disease.

[0242] Clause 63. The method of any one of clauses 55 to 62, wherein the nanovesicles are administered intravenously.

[0243] Clause 64. The method of any one of clauses 55 to 62, wherein the nanovesicles are administered to the subject weekly, twice monthly, or monthly.

[0244] Clause 65. The method of any one of clauses 55 to 64, further comprising administering to the subject a therapeutically effective amount of an additional therapeutic agent.

[0245] Clause 66. The method of any one of clauses 55 to 65, wherein the subject is a human.

[0246] Clause 66.1. The method according to any one of clauses 55 to 66, wherein the cardiac disorder is heart failure.

[0247] Clause 66.2. The method of any one of clauses 55 to 66, wherein the cardiac disorder is a cardiomyopathy.

[0248] Clause 66.3. The method of any one of clauses 55 to 66, wherein the cardiac disorder is ischemia-reperfusion injury.

[0249] Clause 67. A composition for use in treating or inhibiting a disorder in a subject, comprising a therapeutically effective amount of isolated nanovesicles derived from extracellular matrix, the nanovesicles containing interleukin (IL)-33 and containing lysyl oxidase, the nanovesicles a) expressing neither CD63 nor CD81, or b) expressing CD63. lo CD81lo and the disorder is a) organ or tissue fibrosis; b) parenchymal organ graft rejection; or c) cardiac disease other than myocardial infarction.

[0250] Clause 68. The composition described in clause 67, wherein the extracellular matrix is ​​a mammalian extracellular matrix.

[0251] Clause 69. The composition described in Clause 67, wherein the mammalian extracellular matrix is ​​a human extracellular matrix.

[0252] Clause 70. The composition of any one of clauses 67 to 69, wherein the extracellular matrix is ​​derived from esophageal tissue, urinary bladder, small intestinal submucosa, dermis, umbilical cord, pericardium, cardiac tissue, or skeletal muscle.

[0253] Clause 71. The composition according to any one of clauses 67 to 70, wherein the nanovesicles comprise miR-145 and / or miR-181.

[0254] Clause 72. The composition of any one of clauses 67 to 71, wherein the disorder is solid organ graft rejection and the subject is a recipient of a transplanted solid organ.

[0255] Clause 73. The composition of clause 70, wherein the nanovesicles are formulated for administration to a transplanted solid organ.

[0256] Clause 74. The composition according to clause 73, wherein the transplanted solid organ is the heart.

[0257] Clause 75. The composition according to any one of clauses 65 to 71, wherein the disorder is a heart disease.

[0258] Clause 76. The composition according to clause 75, wherein the cardiac disease is cardiac failure or cardiac ischemia.

[0259] Clause 77. The composition according to clause 75, wherein the cardiac disease comprises acute coronary syndrome, chronic stable angina, unstable angina, angioplasty, transient ischemic attack, ischemic reperfusion injury, claudication, vascular occlusion, arteriosclerosis, heart failure, chronic heart failure, acute decompensated heart failure, cardiac hypertrophy, cardiac fibrosis, aortic valve disease, aortic or mitral stenosis, cardiomyopathy, atrial fibrillation, cardiac arrhythmia, and pericardial disease.

[0260] Clause 78. The composition of any one of clauses 67 to 77, wherein the nanovesicles are formulated for intravenous administration.

[0261] Clause 79. The composition according to any one of clauses 67 to 71, wherein the disorder is organ or tissue fibrosis.

[0262] Clause 80. The composition according to clause 79, wherein the fibrosis is liver cirrhosis, pulmonary fibrosis, cardiac fibrosis, mediastinal fibrosis, arthrofibrosis, bone marrow fibrosis, nephrogenic systemic fibrosis, keloid fibrosis, scleroderma fibrosis, renal fibrosis, lymphoid tissue fibrosis, arterial fibrosis, capillary fibrosis, vascular fibrosis, or pancreatic fibrosis.

[0263] Clause 81. The composition according to clause 80, wherein the fibrosis is pulmonary fibrosis.

[0264] Clause 82. The composition according to clause 80, wherein the fibrosis is cardiac fibrosis.

[0265] Article 83. Cardiac fibrosis: a) hypertrophic cardiomyopathy, sarcoidosis, chronic renal failure, toxic cardiomyopathy, ischemia-reperfusion injury, acute organ rejection, chronic organ rejection, aging, chronic hypertension, nonischemic dilated cardiomyopathy, arrhythmias, atherosclerosis, HIV-associated chronic vascular disease, and pulmonary hypertension; or b) Myocardial infarction or myocardial ischemia 83. The composition according to claim 82,

[0266] Clause 83. A composition according to any one of clauses 67 to 81, wherein the nanovesicles are administered to a patient by inhalation.

[0267] Clause 84. The composition of any one of clauses 67 to 83, wherein the nanovesicles are administered to the subject weekly, twice monthly, or monthly.

[0268] Clause 85. The composition of any one of clauses 67 to 84, further comprising a therapeutically effective amount of an additional therapeutic agent.

[0269] Clause 86. The composition of clause 85, wherein the additional therapeutic agent is an immunosuppressant.

[0270] Clause 87. The composition according to clause 86, wherein the immunosuppressant is a calcineurin inhibitor, an antiproliferative agent, an mTOR inhibitor, and / or a steroid.

[0271] Clause 88. The composition according to clause 87, wherein the calcineurin inhibitor is tacrolimus or cyclosporine, the antiproliferative agent is mycophenolic acid, the mTOR inhibitor is sirolimus, and / or the steroid is prednisone, hydrocortisone, or cortisone.

[0272] Clause 89. The composition according to any one of clauses 67 to 88, wherein the subject is a human.

[0273] Clause 90. A method for increasing myoblast differentiation, comprising: contacting myoblasts with an effective amount of isolated extracellular matrix derived nanovesicles, the nanovesicles containing interleukin (IL)-33 and containing lysyl oxidase, the nanovesicles being either: a) not expressing CD63 or CD81; or b) expressing CD63. lo CD81 lo

[0033] Thereby, a method for increasing myoblast differentiation.

[0274] Clause 91. The method of clause 90, wherein the myoblasts are in vitro.

[0275] Clause 92. The method of clause 90 or clause 91, wherein the extracellular matrix is ​​a mammalian extracellular matrix.

[0276] Clause 93. The method of clause 92, wherein the mammalian extracellular matrix is ​​a human extracellular matrix.

[0277] Clause 94. The method of any one of clauses 90 to 93, wherein the extracellular matrix is ​​derived from esophageal tissue, urinary bladder, small intestinal submucosa, dermis, umbilical cord, pericardium, cardiac tissue, or skeletal muscle.

[0278] Clause 95. The method of any one of clauses 90 to 94, wherein the nanovesicles comprise miR-145 and / or miR-181.

[0279] Clause 96. The method of any one of clauses 90 to 95, wherein the myoblasts are in a mammalian subject.

[0280] Clause 97. The method of clause 96, wherein the mammalian subject is a human.

[0281] Clause 98. A method for treating or inhibiting a disorder in a subject having or at risk of having the disorder, comprising the steps of selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated extracellular matrix derived nanovesicles, the nanovesicles containing interleukin (IL)-33 and containing lysyl oxidase, the nanovesicles a) expressing neither CD63 nor CD81, or b) expressing CD63 lo CD81 lo and b. administering to the subject a therapeutically effective amount of a compound selected from the group consisting of ribozyme, ribozyme, serotonin ...

[0282] Clause 99. The method of clause 98, wherein the extracellular matrix is ​​a mammalian extracellular matrix.

[0283] Clause 100. The method of clause 99, wherein the mammalian extracellular matrix is ​​a human extracellular matrix.

[0284] Clause 101. The method of any one of clauses 98 to 100, wherein the extracellular matrix is ​​derived from esophageal tissue, urinary bladder, small intestinal submucosa, dermis, umbilical cord, pericardium, cardiac tissue, or skeletal muscle.

[0285] Clause 102. The method of any one of clauses 98 to 101, wherein the nanovesicles comprise miR-145 and / or miR-181.

[0286] Clause 103. The method of any one of clauses 98 to 102, wherein the disorder is myocardial ischemia.

[0287] Clause 104. The method according to any of clauses 98 to 102, wherein the disorder is myocardial infarction.

[0288] Clause 105. The method of any one of clauses 98 to 104, wherein the nanovesicles are administered intravenously.

[0289] Clause 106. The method of any one of clauses 98 to 105, wherein the nanovesicles are administered to the subject weekly, twice a month, or monthly.

[0290] Clause 107. The method of any one of clauses 98 to 106, further comprising administering to the subject a therapeutically effective amount of an additional therapeutic agent.

[0291] Clause 108. The method of any one of clauses 98 to 107, wherein the subject is a human.

[0292] The present disclosure is illustrated by the following non-limiting examples. EXAMPLES

[0293] Myocardial ischemia induces fibrosis after damaged cardiac myocytes are replaced by fibroblasts and associated excess extracellular matrix (ECM), leading to increased myocardial stiffness and heart failure. Fibrosis also contributes to chronic cardiac allograft rejection, which causes loss of >50% of the graft within 11 years after transplantation (Tx). No therapeutic modalities are available to prevent or reverse fibrosis following cardiac injury.

[0294] Immunosuppressants are ineffective against the pathogenic remodeling process that leads to allograft fibrosis. IL-33 is an IL-1 family member that is commonly found in the nuclei of stromal cells and is generally considered an alarmin or autologous molecule that is released after tissue injury to activate immune cells via the IL-33 receptor, ST2. Emerging evidence indicates that IL33 promotes cardiovascular and skeletal muscle repair by stimulating ST2+ regulatory T cells (Tregs). However, previously described methods of using IL-33 to promote tissue repair rely solely on the use of soluble IL-33 cytokines and may have off-target effects given the large number of cells that express ST2. There remains a need for new methods to deliver IL-33 and new methods of treating various conditions in which IL-33 plays a role, including but not limited to cardiac disease.

[0295] ECM scaffolds are FDA approved for a number of clinical applications, including cardiac repair. Phase I trials are currently underway investigating the use of intracardiac injections of ECM hydrogels following myocardial infarction, but the mechanisms by which ECM directs cardiac tissue remodeling are only partially understood. It is disclosed herein that matrix-bound nanovesicles (MBVs) embedded in ECM scaffolds are a rich source of extranuclear interleukin-33 (IL-33). bIL-33 is typically found in the nuclei of interstitial cells and is generally considered an alarmin that alerts the immune system to cellular injury, resulting in the production of pro-inflammatory mediators with the IL-33 receptor, ST2. Evidence suggests that IL-33 may function as a promoter of tissue repair, particularly in models of cardiovascular disease where induction of IL-33 following cardiac stress correlates with improved outcomes. It has been determined that IL-33 is stably stored within the ECM and protected from inactivation by incorporation into MBVs. From the results, IL33 + / + MBV derived from mouse tissue induces ST2 to promote reparative remodeling M2 phenotype - / - Macrophage differentiation is regulated by IL33 - / - We show that MBVs derived from mouse tissues fail to direct it, further suggesting that MBV-associated IL-33 modulates macrophage activation by a non-canonical ST2-independent pathway. The discovery that IL-33 is an essential component of ECM-MBVs provides mechanistic insight into the regulation of immune-driven pathological fibrosis. ECM scaffolds can be used for cardiac repair. Example 1 Matrix-bound nanovesicles isolated from ECM bioscaffolds contain full-length IL-33

[0296] Isolation of MBVs from ECM bioscaffolds and characterization of miRNA cargo have been previously described (Huleihel et al., Sci Adv 2, e1600502 (2016); Huleihel et al., Tissue Eng part A 23, 1283-1294 (2017)). To identify protein signaling molecules associated with MBVs, a preliminary cytokine, chemokine, and growth factor screen was performed using decellularized wild-type (wt) mouse small intestine or decellularized il33 - / - This was performed using MBVs isolated from mouse small intestine using the Mouse XL Cytokine Array Kit from R&D Systems (Figure 1A). Quantification of the proteins with the highest expression levels in MBVs revealed that IL-33 was the most abundant protein in MBVs isolated from wt mice (IL33 + MBV) il33 - / - MBV isolated from mice (IL33 -The results showed that IL-33 associated with MBVs was highly expressed compared to IL-33 associated with WT mouse intestine, with minimal differences in expression of other proteins present in the isolated MBVs (Figure 1B). Additionally, transmission electron microscopy imaging of MBVs isolated from decellularized WT mouse intestine showed that these vesicles were approximately 100 nm in diameter (Figure 1C). The results from the cytokine screen were further validated by immunoblot analysis, which showed that the IL-33 associated with MBVs was the full-length (32 kDa) form of the protein (Figure 1D) and not a smaller described cleavage product (Lefrancais et al., Proceedings of the National Academy of Sciences 109, 1673-1678 (2012); Cayrol et al., Nature immunology 19, 375 (2018)). The presence of full-length IL-33 expression in MBVs was then observed in ECM surgical meshes commonly used in clinical applications, including laboratory-made and commercially available equivalents, urinary bladder matrix (UBM) and ACELL® MATRISTEM™; small intestinal submucosa (SIS) and Cook Biotech® BIODESIGN™; dermis and BD® XENMATRIX™; and cardiac ECM (Figure 1E). Results showed that IL-33 expression levels in laboratory-made scaffolds were similar to their respective commercially available counterparts, indicating that these results were not an artifact of the laboratory manufacturing protocol. Example 2 IL-33 is stored within the lumen of MBVs and protected from proteolysis

[0297] To verify that the detected IL-33 was not a contaminant of the MBV isolation process, MBV was further purified by molecular sieve chromatography (SEC) using SEPHAROSE® CL-2B resin with continuous monitoring of the eluted fractions by UV absorbance at 280 nm (Figure 2A). Immunoblot analysis confirmed the presence of IL-33 in the heavy MBV fractions (Figure 2B, top panel). In a separate experiment, MBV was first lysed with 1% TRITON® X-100 and the extract was then analyzed by SEC. The results indicate that molecular components from the lysed MBV were predominantly eluted in the lighter fractions, as determined by a shift in the UV chromatogram (Figure 2A) and by immunoblot analysis (Figure 2B, bottom panel). Furthermore, transmission electron microscopy of pooled fractions 6-8 showed the presence of vesicles in these fractions (Figure 2C). These results confirmed that IL-33 was associated with MBVs and not a soluble contaminant of MBV isolates. We next determined whether IL-33 was present on the surface membrane of MBVs or stored within the lumen. Pooled MBVs from fractions 6–8 were biotinylated with NHS-LC-biotin. The sulfonate group prevents biotin from penetrating the lipid membrane, thereby labeling only the outer surface proteins (Diaz et al., Scientific reports 6, 37975 (2016)). After biotinylation, MBVs were lysed and subjected to a streptavidin pull-down assay to fractionate surface proteins from unbound luminal components. Immunoblot analysis showed that IL-33 was present only in the unbound fraction and was not pulled down by streptavidin (SA) beads (Figure 2D). In another experiment, MBVs were first dissolved with 1% TRITON® X-100 and then subjected to biotinylation. This allowed both the surface and luminal components of MBVs to be biotinylated. Immunoblot analysis showed that IL-33 was bound to SA beads after streptavidin pulldown (Figure 2D). Cumulatively, these data suggested that IL-33 was stored in the lumen of MBVs.To confirm these results, a proteinase K protection assay was performed. MBVs from pooled fractions 6-8 were incubated with increasing concentrations of proteinase K in the absence or presence of 1% TRITON® X-100 at 37°C for 30 min. As shown by immunoblot analysis (Figure 2E), in the absence of TRITON® X-100, IL-33 was not degraded by proteinase K. However, permeabilization of the MBV membrane with TRITON® X-100 made IL-33 accessible to proteinase K, making IL-33 susceptible to proteinase K and resulting in IL-33 degradation (Figure 2E). These results confirmed that MBV-associated IL-33 resides within the lumen of the vesicle membrane where it is protected from proteolysis. Example 3 IL33 + MBV activates a pro-remodeling macrophage phenotype by a non-canonical ST2-independent pathway

[0298] IL-33 + or IL-33 - We performed an extensive mechanistic investigation of the effects of MBV on myeloid cells in vitro. Given the location of IL-33 within the lumen of MBV, it was hypothesized that encapsulation of IL-33 would prevent binding to its cognate ST2 receptor, suggesting the existence of an ST2-independent transduction mechanism. To investigate this scenario, we transduced B6 wt mice (Figure 3A) or ST2 - / - Bone marrow-derived macrophages (BMDMs) isolated from mice (Figure 3B) were stimulated with interferon-γ (IFN-γ) and lipopolysaccharide (LPS) to induce an M1-like macrophage phenotype, and with interleukin-4 (IL-4) to induce an M2-like phenotype, recombinant IL-33, MBV isolated from decellularized wt mouse intestine (IL33). + MBV), or il33 - / - Mouse intestine (IL33 -Macrophages were stimulated with IL-4-stimulated (M2) cells, or with MBV isolated from porcine small intestinal submucosa (SIS MBV). Results showed that macrophages expressed SIS MBV and IL33, similar to the expression pattern of IL-4-stimulated (M2) cells. + We showed that IL-33 expressed arginase 1 (Arg-1) in response to MBV (Figures 3A and 3D). - MBV induced the expression of iNOS, but not Arg-1 (Figures 3A and 3C). - / - A similar effect was observed using macrophages isolated from mice. + MBV is st2 - / - IL33 directed macrophage activation toward a reparative, pro-remodeling M2-like phenotype - The results from the immunolabeling assay were then confirmed by Western blot analysis, which showed that macrophages were IL33-dependent. + Stimulation with MBV can induce upregulation of Arg-1 expression, whereas IL33 - We showed that MBV was unable to do this (Figure 4A). + MBV activates M2 macrophages in a STAT6 phosphorylation-independent manner, and this IL33 + The ability of MBV to induce Arg-1 expression was shown to be distinct from the well-characterized IL-4 / IL-13-mediated M2 macrophage differentiation pathway (Figure 4B). These data demonstrate that MBV-associated IL-33 modulates macrophage activation through an uncharacterized non-canonical ST2-independent pathway. Example 4 Assessment of myogenesis of skeletal muscle progenitor cells following exposure to macrophage secretions

[0299] The selectively activated M2 macrophage-associated secretome has been shown to be myogenic for skeletal myoblasts 41,42 Previously, we reported that medium conditioned by ECM-treated macrophages enhanced the proliferation of C2C.12 It was shown that myotube formation and sarcomeric myosin expression in myoblasts were promoted. 43 This study is + The medium conditioned by macrophages stimulated with MBV increased C2C 12 Myoblast myotube formation was promoted similarly to the biological activity of M2-like macrophages induced by IL-4, whereas IL33 - Similar results were observed in that it was not promoted by medium conditioned by macrophages stimulated with MBV. (Figure 5A, B). Example 5 Materials and Methods for Examples 1-4

[0300] Decellularization of mouse intestine: Fresh small intestine was cultured from adult wild-type (wt) B6 mice or adult IL-33 - / - Small intestines were obtained from B6 mice. The small intestines were washed with phosphate-buffered saline (PBS) to completely remove all intestinal contents, and 1.5 cm long fragments were obtained from each intestine for immediate decellularization. Samples were prepared as previously described (Oliveira AC, et al. PLoS ONE. 2013; 8 (6): e66538) decellularized. Briefly, samples were first immersed in 5M NaCl for 72 hours under continuous gentle agitation. The decellularization solution was changed every 24 hours. Mouse intestinal ECM was then freeze-dried and crushed into particulates using a Wiley Mill with a #40 mesh screen.

[0301] Preparation of skin ECM: Skin ECM was prepared as previously described (Reing JE, et al. Biomaterials. 2010; 31 (33): 8626-33). Briefly, full thickness skin was harvested from market weight (approximately 110 kg) pigs (Tissue Source Inc.) and subcutaneous fat and epidermis were removed by mechanical delamination. The tissue was then treated with 0.25% trypsin (Thermo Fisher Scientific) for 6 h, 70% ethanol for 10 h, 3% H2O2 for 15 min, 1% TRITON® X-100 in 0.26% EDTA / 0.69% Tris (Sigma-Aldrich) for 6 h, with a change of solution for an additional 16 h, and 0.1% peracetic acid / 4% ethanol (Rochester Midland) for 2 h. Water washes were performed between each chemical change, with alternating water and phosphate-buffered saline (PBS) washes after the final step. All chemical exposures were performed on an orbital shaker with agitation at 300 rpm. The dermal ECM was then freeze-dried and ground into particulates using a Wiley Mill with a #40 mesh screen.

[0302] Preparation of Urinary Bladder Matrix (UBM): UBM was prepared as previously described (Mase VJ, et al. Orthopedics. 2010; 33 (7): 511). Porcine bladders from market weight animals were obtained from Tissue Source, LLC. Briefly, the serosa, muscularis externa, submucosa, and muscularis mucosa were mechanically removed. The luminal urothelial cells of the mucosa were dissociated from the basement membrane by washing with deionized water. The remaining tissue, consisting of the basement membrane and the underlying lamina propria of the mucosa, was decellularized by agitation at 300 rpm for 2 hours in 0.1% peracetic acid with 4% ethanol. The tissue was then rinsed extensively with PBS and sterile water. The UBM was then freeze-dried and crushed into fine particles using a Wiley Mill with a #60 mesh screen.

[0303] Preparation of small intestinal submucosa (SIS): SIS was prepared as previously described (Badylak SF, et al. J Surg Res. 1989; 47 (1): 74-80). Briefly, jejunum was harvested from 6-month-old market weight (~110-~120 kg) pigs and cleaved longitudinally. The superficial layer of mucosa was mechanically removed. Similarly, the serosa and outer muscularis were mechanically removed, leaving the submucosa and basal portion of the mucosa. Decellularization and disinfection of the tissue was completed by agitation at 300 rpm for 2 hours in 0.1% peracetic acid with 4% ethanol. The tissue was then rinsed extensively with PBS and sterile water. The SIS was then freeze-dried and crushed into fine particles using a Wiley Mill with a #60 mesh screen.

[0304] Preparation of cardiac ECM: Cardiac ECM was prepared as previously described (Wainwright JM, et al. Tissue Eng Part C Methods. 2010;16(3):525-32). Briefly, pig hearts were obtained immediately after euthanasia, frozen at -80°C for at least 16 hours, and thawed. The aorta was cannulated and perfused with alternating Type 1 reagent grade (Type 1) water and 2x PBS at 1 liter per minute each for 15 minutes. Stepwise perfusion of 0.02% trypsin / 0.05% EDTA / 0.05% NaN3 at 37°C, 3% TRITON® X-100 / 0.05% EDTA / 0.05% NaN3, and 4% deoxycholic acid was performed (each at approximately 1.2 liters per minute for 2 hours). Finally, the heart was perfused with 0.1% peracetic acid / 4% EtOH at 1.7 liters per minute for 1 hour. After each chemical solution, the hearts were flushed with type 1 water and 2x PBS to aid in cell lysis and removal of cell debris and chemical residues. The cardiac ECM was then lyophilized and ground into particulates using a Wiley Mill with a #60 mesh screen.

[0305] Isolation of matrix-bound nanovesicles (MBVs): MBVs were isolated as previously described (Huleihel L, et al. Sci Adv. 2016;2(6): e1600502). Briefly, enzymatically digested ECM was subjected to successive centrifugations at 500g (10 min), 2500g (20 min), and 10,000g (30 min) to remove collagen fibril remnants. Each of the above centrifugation steps was performed three times. The fibril-free supernatant was then centrifuged at 100,000g for 70 min at 4°C (Beckman Coulter Optima L-90K ultracentrifuge). The 100,000g pellet was washed and diluted with PBS. The mixture was suspended in 500 μl and passed through a 0.22 μm filter (Millipore).

[0306] Cytokine antibody array: Cytokines stored within MBVs were analyzed using the Mouse XL Cytokine Array Kit (R&D Systems; Minneapolis, MN, USA) according to the manufacturer's instructions. Decellularized WT mouse intestine (n=3) or decellularized IL-33 - / - Extracts were prepared from MBV isolated from mouse intestine (n=3). Extracts were diluted and incubated with the array membrane overnight. Arrays were rinsed to remove unbound proteins, incubated with an antibody cocktail, and developed using streptavidin-horseradish peroxidase and chemiluminescence detection reagents. Mean spot pixel density was quantified using Image J software.

[0307] Transmission Electron Microscopy (TEM): TEM imaging was performed on MBVs loaded onto carbon-coated grids and fixed in 4% paraformaldehyde as previously described (Huleihel L, et al. Sci Adv. 2016;2(6): e1600502). Grids were imaged using a JEOL 1210 TEM equipped with a high-resolution Advanced Microscopy Techniques digital camera at 80 kV. MBV sizes were determined from representative images using JEOL TEM software.

[0308] Molecular Exclusion Chromatography (SEC): Fractionation of MBV by SEC was performed as previously described (Boing, AN, et al. J Extracellular Vesicles. 2014; 3(1)). Briefly, 15 ml of Sepharose CL-2B resin (Sigma Aldrich) was layered into a 1 cm x 20 cm glass column, washed with PBS, and equilibrated. 1 ml of MBV was loaded onto the column and fraction collection (0.3 ml per fraction and a total of 30 fractions collected) was started immediately using PBS as the elution buffer. Elution fractions were continuously monitored by UV280nm using a Biologic LP system (BioRad). Dissolved MBV was prepared by incubating MBV in 1% TRITON® X-100 for 30 min, and then subjected to SEC as described above.

[0309] Biotinylation of MBV proteins: Biotinylation of MBV proteins was performed as previously described with minor modifications (Diaz G, et al. Sci Rep. 2016;6: 37975). 100 micrograms of intact MBV was incubated in the absence or presence of 10 mM sulfo-NHS-biotin for 30 minutes at room temperature. The presence of sulfonic acid groups in sulfo-NHS-biotin prevents the reagent from penetrating the MBV membrane. After incubation, excess sulfo-NHS-biotin was removed using a 10 kDa MWCO filtration column, and then MBV was dissolved with 1% TRITON® X-100. In another experiment, 100 micrograms of MBV was first dissolved in 1% TRITON® X-100. After dissolution, a buffer exchange was performed to replace the 1% TRITON® X-100 solution with 1×PBS. MBV extracts were then incubated in the absence or presence of 10 mM sulfo-NHS-biotin for 30 min at room temperature. After incubation, excess sulfo-NHS-biotin was removed using a 10 kDa MWCO filtration column. MBV ± biotin or MBV extract ± biotin was diluted to 500 μl in 1× PBS and incubated with 50 μl prewashed streptavidin-sepharose resin (Sigma Aldrich). After 2 h incubation at room temperature on an orbital rocker, the streptavidin-sepharose resin was pelleted by centrifugation at 10,000×g for 5 min. The supernatant, representing the unbound fraction, was transferred to a new tube and the resin was washed 5 times with 300 mM NaCl. Bound proteins were eluted from the resin by incubation with elution buffer (2% SDS, 6 M urea) for 15 min at room temperature and then at 96° C. for 15 min.

[0310] Proteinase K protection assay: Proteinase K protection assay was performed as previously described (de Jong OG, et al. J Cell Mol Med. 2016;20(2): 342-350). Briefly, MBV were incubated in PBS or increasing concentrations of proteinase K in PBS with or without the presence of 1% TRITON® X-100 in a final volume of 20 μl per sample at 37° C. for 1 h. The assay was stopped by adding 20 μl of 2× Laemmli Buffer at 95° C. containing 10 mM DTT. After 5 min of incubation at 95° C., samples were used for immunoblot analysis.

[0311] Macrophage isolation and activation: Murine bone marrow-derived macrophages (BMDMs) were isolated and characterized as previously described (Huleihel L, et al. Tissue Eng part A. 2017; 23 (21-22): 1283-1294). Briefly, bone marrow was harvested from 6-8 week old C57bl / 6 mice. Cells harvested from bone marrow were washed and cultured at 1 × 10 cells per mL. 6 The cells were plated at 100x and differentiated into macrophages in the presence of macrophage colony-stimulating factor (MCSF) for 7 days with complete medium changes every 48 hours. Macrophages were then activated for 24 hours with one of the following: (1) M IFNγ+LPS to promote a phenotype (M1-like), 20 ng / mL interferon-γ (IFNγ) and 100 ng / mL lipopolysaccharide (LPS) (Affymetrix eBioscience, Santa Clara, CA; Sigma Aldrich), (2) M IL-4 To promote a (M2-like) phenotype, we added 20 ng / mL interleukin (IL)-4 (Invitrogen), (3) 100 ng / ml IL-33 (Peprotech), or (4) 25 μg / mL WT mouse MBV, IL-33 - / -MBV, or SIS-MBV. After an incubation period at 37°C, cells were washed with sterile PBS and fixed with 2% paraformaldehyde (PFA) for immunolabeling.

[0312] Macrophage immunolabeling: To prevent non-specific binding, cells were incubated in blocking solution consisting of PBS, 0.1% TRITON®-X, 0.1% TWEEN®-20, 4% goat serum, and 2% bovine serum albumin at room temperature for 1 hour. The blocking buffer was then removed and cells were incubated in a solution of one of the following primary antibodies: (1) monoclonal anti-F4 / 80 (Abcam, Cambridge, MA), diluted 1:200, as a pan-macrophage marker, (2, 3) polyclonal anti-inducible nitric oxide synthase (iNOS) (Abcam, Cambridge, MA), diluted 1:100, as an M1-like marker, and anti-arginase 1 (Abcam, Cambridge, MA), diluted 1:200, as an M2-like marker. Cells were incubated at 4°C for 16 hours, the primary antibody was removed, and cells were washed with PBS. A solution of secondary antibodies conjugated with a fluorophore (Alexa donkey anti-rabbit 488 or donkey anti-rat 488; Invitrogen, Carlsbad, CA) was added to the appropriate wells and left at room temperature for 1 hour. The antibodies were then removed, the cells washed with PBS, and the nuclei were counterstained using DAPI. Cytokine-activated macrophages were used to establish a standard exposure time (positive control), which was then kept constant throughout the groups. Images were quantified using CellProfiler (Broad Institute, Cambridge, MA). Data were analyzed for statistical significance using either an unpaired Student's t-test comparing treated macrophages to the appropriate M0 media control, or a one-way ANOVA with Tukey's post-hoc test for multiple comparisons. Data were reported as mean ± standard deviation with a minimum N=3. A p-value <0.05 was considered statistically significant.

[0313] C2C 12Myogenesis assay: High serum medium (20% fetal bovine serum) maintains cell proliferation within the cell cycle and inhibits differentiation. Conversely, low serum medium (1% fetal bovine serum, 1% horse serum) induces cell cycle exit and myotube formation and serves as a positive control. These are referred to as proliferation medium and differentiation medium, respectively. Muscle differentiation potential was determined by examining the fusion index of skeletal myoblasts. C2C 12 Skeletal myoblasts were cultured in growth medium until they reached approximately 80% confluence. The medium was then replaced with treatment medium consisting of a 50:50 solution of macrophage supernatant and growth medium or control, which was growth medium or differentiation medium. After 5–7 days, or when differentiation medium control showed myotube formation, cells were fixed with 2% paraformaldehyde for immunolabeling. Fixed cells were blocked for 1 h at room temperature according to a previously described protocol and incubated in anti-sarcomeric myosin antibody. After primary incubation, cells were washed with PBS and incubated in Alexa Fluor donkey anti-mouse 488 secondary antibody at a dilution of 1:200 for 1 h at room temperature and counterstained with DAPI. For each well, five 20x fields of images were acquired using a Zeiss Axiovert microscope. Example 6 IL-33 and MBV in graft rejection

[0314] Acute heart transplant (HTx) rejection is generally characterized by the recipient's CD4+ receptor mediated cytotoxicity against alloantigens. + and CD8 +This is prevented by immunosuppressant therapy, which controls the T cell response. However, such immunosuppressive treatment is ineffective against chronic cardiac transplant rejection (CR), and the resulting immune-mediated fibrosis and vascular remodeling leads to progressive myocardial dysfunction and the loss of the majority of HTx within approximately 11 years after transplantation. Recent studies have shown that innate immune cells, such as inflammatory macrophages, monocytes, and monocyte-derived dendritic cells (DCs), play a key role in CR due to their potent proinflammatory response to damage-associated molecular patterns (DAMPs) released after ischemia-reperfusion injury (IRI) associated with the transplantation process. Parenchymal organs are rapidly infiltrated by recipient monocytes and recipient monocyte-derived DCs, which act as important local stimuli for alloreactive T cells that initiate and sustain CR. Thus, it is clear that self-molecules containing damage-associated molecular patterns are released during tissue injury and stimulate a proinflammatory response in infiltrating innate immune cells. However, the local endogenous negative regulators that are also present at the site of injury to control the immune response are not well understood. IL-33, an IL-1 family member sequestered in the nuclei of stromal cells, may have such immunomodulatory properties. Delivery of recombinant IL-33 promotes graft survival after cardiac transplantation by expanding regulatory T cells (Tregs). It is disclosed herein that MBVs isolated from the ECM of various organs have been found to be an abundant and stable source of IL-33. Although it is understood that IL-33 is a nuclear protein, a mechanism is lacking that releases IL-33 from nuclear sequestration and allows IL-33 to mediate effects on immune cells. The data presented herein establish that IL-33 in MBVs is an important source of unsequestered immunomodulatory IL-33 that can direct innate immune cell differentiation in vitro and in vivo. Example 7 Absence of IL-33 increases chronic rejection

[0315] In vitro studies revealed a strong ability to shift macrophages towards the immunoregulatory and potentially reparative M2 subset (Figures 3A-3C, 4A-4B). To test the impact of IL-33, including that located within the MBV, on cardiac transplant outcomes, hearts from IL-33-deficient or IL-33-sufficient Bm12 mice were transplanted into wild-type (WT) C57BL / 6 (B6) recipient mice. These mice lack IL-33 in both the nucleus and MBV. Bm12 mice express H2-Ab1 b H2-Ab1 differs from H2-Ab1 by three nucleotides, resulting in three amino acid substitutions that are recognized as non-self by the immune system of WT B6 mice. bm12 In these studies, Bm12 grafts deficient in IL-33 (KO) or sufficient for IL-33 (WT) were transplanted into B6 recipients, and the occurrence of vascular occlusion and fibrosis associated with chronic rejection was evaluated 90–100 days after transplantation (Figure 6A–6D). Hematoxylin and eosin (H+E; Figure 6A) and trichrome staining (Figure 6B) and computer-assisted image analysis confirmed that HTx lacking IL-33 exhibited significantly increased vasculopathy (Figure 6C) and muscle fiber loss / fibrotic disease (Figure 6D). Thus, the total absence of IL-33 unambiguously increased the occurrence of chronic rejection. Example 8 IL-33 + MBV regulates the generation of inflammatory myeloid cells after transplantation

[0316] In mechanistic studies, graft IL-33 and IL-33 + We investigated the impact of completely lacking reconstruction of MBV, specifically, how this affects local immune cells orchestrating chronic rejection. In these studies, leukocytes were isolated and assessed by flow cytometric analysis on day 3 post-surgery. Leukocytes isolated from naive Bm12 mouse hearts (naive control) were included as baseline controls (n = 4). Representative dot plots (Figures 7A-7D) were generated from the flow cytometric analysis, and their statistical analysis is shown (P values ​​were generated by one-way analysis of variance (ANOVA)).* P < 0.05, ** P < 0.01, *** P<0.005, **** P < 0.001). Heart transplants lacking IL-33 significantly increased the number of monocyte-derived dendritic cells (monoDCs) (Figures 7A-7B: CD45 + CD11b + CD11c + F4-80 lo MHCII hi ) and inflammatory macrophages (Figures 7C-7D; CD45 + CD11b + F4-80 hi Ly6c hi MHCII hi The early inflammatory response, exemplified by the presence of local inflammatory myeloid cells such as IL-33, was significantly increased. + This could be corrected by local IL-33 restoration using MBV (Figures 8A-8D). hi monoDCs (Figures 8A and 8C) and CD11b+F4 / 80 hi Ly6c hi This is demonstrated by a significant reduction in inflammatory macrophages (Figures 8B, 8D). Together, these data identify IL-33 within MBVs as a key local factor controlling the generation of inflammatory myeloid cells in the graft following transplantation.

[0317] Reduction of local inflammation can limit the occurrence of early rejection and subsequent chronic rejection. All solid organs (heart, kidney, liver, lung) are subject to a form of chronic rejection accompanied by fibrotic disease and accelerated vascular pathology. Based on findings in commonly used rodent solid transplant models, local IL-33 immediately following other solid organ transplants may be beneficial. +MBV delivery acts to limit the inflammatory potential of local myeloid cells, promoting improved transplant outcomes. Inflammation due to extended ischemic times and early tissue damage after solid organ transplantation is associated with poor transplant outcomes and increased acute and chronic rejection. Conversely, best transplant outcomes are observed after living donor transplantation when inflammatory responses mediated by infiltrating innate myeloid cells are reduced / limited by short ischemic times. Current immunosuppressant agents utilized after transplantation primarily target adaptive immune cells (T and B cells). They are ineffective against innate immune cells, with the exception of steroids. These drugs generally do not exert a strong effect on innate cells that initiate the rejection response. Thus, the combination of MBV to target innate myeloid cells with an immunosuppressant that targets adaptive immune cells is a highly effective combination. Example 9 Materials and Methods for Examples 7-8

[0318] Animals: C57BL / 6 (B6) and Bm12 mice were purchased from Jackson Laboratories. - / - Mice were provided by S. Nakae (University of Tokyo, Tokyo, Japan). 84 The Bm12 mice were donated by the IL33 - / - by backcrossing six times against the Bm12 × il33 background - / - We generated mice. St2 - / - The mouse was originally 85 Mice were generated on a BALB / c background and obtained from Dr. Anne Sperling (University of Chicago) after seven backcrosses onto a C57BL / 6 background. These mice were then backcrossed onto a C57BL / 6 background three more times. Animals were housed in a specific pathogen-free facility.

[0319] Vascularized heart transplantation: H2-Ab1 as a cardiac donor in a mouse model of chronic rejection b B6 Bm12, which has three amino acid substitutions in IL-33 compared to wild-type (WT) B6 mice, is commonly used. By crossing Bm12 mice with IL-33-deficient B6 mice, we were able to define the role of IL-33 in chronic rejection. Bm12 or Bm12 × il33 - / - Hearts were cultured in C57BL / 6 or C57BL / 6 il33 - / - The donor hearts were transplanted heterotopically into the recipient abdomen. Briefly, donor hearts were transplanted into recipients by end-to-side anastomosis of the donor ascending aorta and pulmonary artery to the recipient abdominal aorta and inferior vena cava, respectively. Graft function was assessed daily by abdominal palpation for cardiac contraction. In some experiments, IL-33 + MBV was diluted in porcine-derived UBM hydrogel to a final concentration of 1 mg / ml MBV. After reperfusion of the graft, the graft was covered with hydrogel containing 40 μg of diluted MBV. The gut was replaced and allowed to reoccupy its normal position around the transplanted heart while the MBV in the hydrogel was stably attached to the cardiac surface. Graft function was verified by abdominal palpation for cardiac contractions daily until the indicated harvest date.

[0320] Isolation of spleen and graft-infiltrating leukocytes: Mice were anesthetized and perfused with PBS + 0.5% heparin through the left ventricle until the fluid leaving the right ventricle contained no visible blood. Spleens were isolated and single cell suspensions were generated after mechanical dissociation and RBX lysis. Hearts were then removed, cut into pieces, and dissociated using program E on a gentleMACS dissociator (Miltenyi Biotec) using the GentleMACS The cells were homogenized in medium containing 350 μl / ml collagenase type IV and 1 μl / ml DNAse I in tube C. Single cell suspensions were then obtained by filtration through a 40 μm cell strainer and centrifugation at 1500 g for 20 min on a Lympholyte-M (Cedarlane) density gradient. Cells were removed during interphase using a Pasteur pipette and transferred to a new tube for washing, cell counting, and analysis.

[0321] Flow cytometry: Isolated splenocytes and graft-infiltrating leukocytes were incubated with heat-inactivated goat serum (5%) to block FcR, processed with live / dead stains, and then labeled with various combinations of fluorochrome-conjugated Abs (BD Bioscience, Biolegend, eBioscience, or MD Biosciences) to assess myeloid cell populations. Data were acquired on a LSRFortessa flow cytometer (BD Biosciences) and analyzed using FlowJo, Version 10.1 (TreeStar).

[0322] Histological and immunohistochemical staining: Naïve mouse hearts and cardiac explants were formalin-fixed, paraffin-embedded, sectioned at 4 μm, and stained with H+E or Masson's Trichrome according to standard protocols. Fibrosis was visualized by blue staining using NearCYTE software (available on the Internet at nearctye.org). + Area (mm 2 ) to the total tissue area (mm 2 ) and multiplied by 100 to yield the % fibrosis area measurement. The percentage of arterial occlusion was calculated by manually comparing occluded arteries relative to the total number of arteries in each cardiac sample. Example 10 Treatment of fibrosis

[0323] Human lung fibroblasts were isolated from explanted lungs of patients with interstitial pulmonary fibrosis (IPF) and age-matched normal (control) patients. Expression levels of fibrosis markers Col1, Col3, fibronectin, and ACTA2 were determined before and after treatment with MBV. MBV were isolated from three different source tissues: porcine decellularized bladder matrix (UBM), porcine decellularized lung (pLung), and human lung tissue (hLung). MBV were added to the culture medium at two different concentrations (1 × 10 particles per ml). 9 pcs and 3×10 9 The MBVs were added at 100 mg / mL (100 mg / mL) to the lungs. The results showed that all treatments significantly reduced the expression levels of these fibrosis markers. More significant reductions were achieved with MBVs isolated from decellularized lungs. See Figures 9A, 9B. Thus, administration of MBVs can be used as a therapy to reduce fibrosis in lungs and other tissues.

[0324] It will be apparent that the precise details of the methods or compositions described may be varied or modified without departing from the spirit of the described invention, and we claim all such modifications and variations that come within the scope and spirit of the following claims. The present invention provides, for example, the following items. (Item 1) 1. A method for treating or inhibiting a disorder in a subject having or at risk of having the disorder, comprising: selecting a subject having or at risk of having said disorder; administering to the subject a therapeutically effective amount of isolated extracellular matrix derived nanovesicles, wherein the nanovesicles contain interleukin (IL)-33 and contain lysyl oxidase, and the nanovesicles a) do not express CD63 or CD81, or b) express CD63. lo CD81 lo Steps and Including, Thereby, said disorder in said subject is treated or inhibited, said disorder being a) organ or tissue fibrosis; b) parenchymal organ transplant rejection; or c) cardiac disease that is not myocardial infarction or myocardial ischemia. (Item 2) 2. The method of claim 1, wherein the extracellular matrix is ​​a mammalian extracellular matrix. (Item 3) 3. The method of claim 2, wherein the mammalian extracellular matrix is ​​a human extracellular matrix. (Item 4) 4. The method of any one of items 1 to 3, wherein the extracellular matrix is ​​derived from esophageal tissue, urinary bladder, small intestinal submucosa, dermis, umbilical cord, pericardium, cardiac tissue, or skeletal muscle. (Item 5) 5. The method according to any one of items 1 to 4, wherein the nanovesicles comprise miR-145 and / or miR-181. (Item 6) 6. The method of any one of items 1 to 5, wherein the disorder is solid organ graft rejection and the subject is a recipient of a transplanted solid organ. (Item 7) 7. The method of claim 6, wherein the nanovesicles are administered to the transplanted solid organ. (Item 8) 8. The method according to item 7, wherein the transplanted solid organ is a heart. (Item 9) 6. The method according to any one of items 1 to 5, wherein the disorder is a cardiac disease. (Item 10) 6. The method according to any one of items 1 to 5, wherein the cardiac disease is heart failure or cardiac ischemia. (Item 11) 6. The method according to any of items 1 to 5, wherein the cardiac disease comprises acute coronary syndrome, chronic stable angina, unstable angina, angioplasty, transient ischemic attack, ischemic reperfusion injury, claudication, vascular occlusion, arteriosclerosis, heart failure, chronic heart failure, acute decompensated heart failure, cardiac hypertrophy, cardiac fibrosis, aortic valve disease, aortic or mitral stenosis, cardiomyopathy, atrial fibrillation, cardiac arrhythmia, and pericardial disease. (Item 12) 12. The method of any one of items 1 to 11, wherein the nanovesicles are administered intravenously. (Item 13) 6. The method according to any one of items 1 to 5, wherein the disorder is organ or tissue fibrosis. (Item 14) Item 14. The method of item 13, wherein the fibrosis is liver cirrhosis, pulmonary fibrosis, cardiac fibrosis, mediastinal fibrosis, arthrofibrosis, myelofibrosis, nephrogenic systemic fibrosis, keloid fibrosis, scleroderma fibrosis, renal fibrosis, lymphoid tissue fibrosis, arterial fibrosis, capillary fibrosis, vascular fibrosis, or pancreatic fibrosis. (Item 15) 15. The method of claim 14, wherein the fibrosis is pulmonary fibrosis. (Item 16) 15. The method of claim 14, wherein the fibrosis is cardiac fibrosis. (Item 17) The cardiac fibrosis is a) hypertrophic cardiomyopathy, sarcoidosis, chronic renal failure, toxic cardiomyopathy, ischemia-reperfusion injury, acute organ rejection, chronic organ rejection, aging, chronic hypertension, nonischemic dilated cardiomyopathy, arrhythmias, atherosclerosis, HIV-associated chronic vascular disease, and pulmonary hypertension; or b) Myocardial infarction or myocardial ischemia Item 17. The method according to item 16, wherein the method is caused by (Item 18) 16. The method of claim 15, wherein the nanovesicles are administered to the patient by inhalation. (Item 19) 17. The method of any one of items 1 to 16, wherein the nanovesicles are administered to the subject weekly, twice monthly, or monthly. (Item 20) 20. The method of any one of items 1 to 19, further comprising administering to the subject a therapeutically effective amount of an additional therapeutic agent. (Item 21) 21. The method of claim 20, wherein the additional therapeutic agent is an immunosuppressant. (Item 22) 22. The method of claim 21, wherein the immunosuppressant is a calcineurin inhibitor, an antiproliferative agent, an mTOR inhibitor, and / or a steroid. (Item 23) 23. The method of claim 22, wherein the calcineurin inhibitor is tacrolimus or cyclosporine, the antiproliferative agent is mycophenolic acid, the mTOR inhibitor is sirolimus, and / or the steroid is prednisone, hydrocortisone, or cortisone. (Item 24) 24. The method of any one of items 1 to 23, wherein the subject is a human. (Item 25) A composition for use in treating or inhibiting a disorder in a subject, comprising a therapeutically effective amount of isolated extracellular matrix derived nanovesicles, said nanovesicles containing interleukin (IL)-33 and containing lysyl oxidase, said nanovesicles being: a) not expressing CD63 or CD81, or b) expressing CD63 or CD81. lo CD81 lo and the disorder is a) organ or tissue fibrosis; b) solid organ transplant rejection; or c) cardiac disease other than myocardial infarction. (Item 26) 26. The composition of item 25, further comprising an additional therapeutic agent. (Item 27) 27. The composition of claim 26, wherein the additional therapeutic agent is an immunosuppressant. (Item 28) 28. The composition of claim 27, wherein the immunosuppressant is a calcineurin inhibitor, an antiproliferative agent, an mTOR inhibitor, and / or a steroid. (Item 29) 23. The composition of claim 22, wherein the calcineurin inhibitor is tacrolimus or cyclosporine, the antiproliferative agent is mycophenolic acid, the mTOR inhibitor is sirolimus, and / or the steroid is prednisone, hydrocortisone, or cortisone. (Item 30) 1. A method for increasing myoblast differentiation, comprising: contacting myoblasts with an effective amount of isolated extracellular matrix derived nanovesicles, wherein said nanovesicles contain interleukin (IL)-33 and contain lysyl oxidase, and wherein said nanovesicles a) do not express CD63 or CD81, or b) express CD63 lo CD81 lo

[0033] Thereby increasing myoblast differentiation. (Item 31) 31. The method of claim 30, wherein the myoblasts are in vitro. (Item 32) 32. The method of claim 30 or 31, wherein the extracellular matrix is ​​a mammalian extracellular matrix. (Item 33) 33. The method of claim 32, wherein the mammalian extracellular matrix is ​​a human extracellular matrix. (Item 34) The method according to any one of items 30 to 33, wherein the extracellular matrix is ​​derived from esophageal tissue, urinary bladder, small intestinal submucosa, dermis, umbilical cord, pericardium, cardiac tissue, or skeletal muscle. 35. The method according to any one of items 30 to 34, wherein the nanovesicles comprise miR-145 and / or miR-181. (Item 36) 36. The method of any one of items 30 to 35, wherein the myoblasts are in a mammalian subject. (Item 37) 37. The method of claim 36, wherein the mammalian subject is a human.

Claims

1. A composition comprising isolated nanovesicles derived from extracellular matrix for use in a method for treating, suppressing or inhibiting cardiac transplant rejection in a subject having a cardiac transplant, the method comprising: administering to said subject said composition, wherein said nanovesicles contain interleukin (IL)-33 and comprise lysyl oxidase, and wherein said nanovesicles a) express neither CD63 nor CD81, or b) are CD63 lo CD81 lo ; The composition thereby treating, suppressing or inhibiting heart transplant rejection in said subject.

2. The composition described in claim 1, wherein the extracellular matrix is ​​a mammalian extracellular matrix.

3. The composition described in claim 2, wherein the mammalian extracellular matrix is ​​derived from bovine, porcine or ovine.

4. The composition described in any one of claims 1 to 3, wherein the extracellular matrix is ​​cardiac ECM.

5. The composition described in any one of claims 1 to 3, wherein the extracellular matrix is ​​derived from the bladder, intestine, liver, heart, esophagus, spleen, stomach, or dermis.

6. The composition of claim 1, wherein the nanovesicles comprise miR-145 and / or miR-181.

7. The composition according to claim 1, wherein the composition is administered intravenously.

8. A composition described in any one of claims 1 to 6, characterized in that the composition is administered to the subject by inhalation.

9. The composition described in any one of claims 1 to 8, characterized in that the composition is administered to the subject weekly, twice a month, or monthly.

10. A composition described in any one of claims 1 to 9, wherein the method further comprises a step of administering to the subject a therapeutically effective amount of an immunosuppressant.

11. The composition of claim 10, wherein the immunosuppressant is a calcineurin inhibitor, an antiproliferative agent, an mTOR inhibitor, and / or a steroid.

12. The composition of claim 11, wherein the calcineurin inhibitor is tacrolimus or cyclosporine, the antiproliferative agent is mycophenolic acid, the mTOR inhibitor is sirolimus, and / or the steroid is prednisone, hydrocortisone, or cortisone.

13. The composition described in any one of claims 1 to 12, wherein the subject is a human.

14. The composition described in any one of claims 1 to 13, wherein the cardiac transplant rejection is acute transplant rejection.

15. The composition described in any one of claims 1 to 13, wherein the cardiac transplant rejection is chronic transplant rejection.

16. A composition for use in treating, suppressing or inhibiting cardiac transplant rejection in a subject, said composition comprising a therapeutically effective amount of isolated extracellular matrix derived nanovesicles, the nanovesicles contain interleukin (IL)-33 and include lysyl oxidase; The nanovesicles a) do not express CD63 or CD81, or b) are CD63 lo CD81 lo ; composition.

17. The composition of claim 16, further comprising an immunosuppressant.

18. The composition of claim 17, wherein the immunosuppressant is a calcineurin inhibitor, an antiproliferative agent, an mTOR inhibitor, and / or a steroid.

19. The composition of claim 18, wherein the calcineurin inhibitor is tacrolimus or cyclosporine, the antiproliferative agent is mycophenolic acid, the mTOR inhibitor is sirolimus, and / or the steroid is prednisone, hydrocortisone, or cortisone.

20. The composition described in any one of claims 16 to 19, wherein the cardiac transplant rejection is acute transplant rejection.

21. The composition described in any one of claims 16 to 19, wherein the cardiac transplant rejection is chronic transplant rejection.

22. The composition described in any one of claims 16 to 21, wherein the extracellular matrix is ​​a mammalian extracellular matrix.

23. The composition of any one of claims 16 to 22, wherein the mammalian extracellular matrix is ​​derived from bovine, porcine or ovine.

24. A composition described in any one of claims 16 to 23, wherein the extracellular matrix is ​​cardiac ECM.

25. The composition of any one of claims 16 to 24, wherein the extracellular matrix is ​​derived from the bladder, intestine, liver, heart, esophagus, spleen, stomach, or dermis.

26. The composition of any one of claims 16 to 25, wherein the nanovesicles contain miR-145 and / or miR-181.

27. The composition of any one of claims 16 to 26, wherein the composition is formulated for intravenous administration.

28. The composition of any one of claims 16 to 26, wherein the composition is formulated for administration by inhalation.

29. The composition described in any one of claims 16 to 28, wherein the subject is a human.

Citation Information

Patent Citations

  • Compositions and methods for preventing cardiac arrhythmias

    JP2012518041A

  • Compositions and methods for cardiac treatment

    JP2013536246A

  • Cardiac fibroblast-derived extracellular matrix and injectable formulations thereof for treatment of ischemic disease or injury

    WO2016197038A1

  • Matrix bound nanovesicles and their use

    WO2017151862A1